MXPA00004956A - Substituted oximes as neurokinin antagonists - Google Patents
Substituted oximes as neurokinin antagonistsInfo
- Publication number
- MXPA00004956A MXPA00004956A MXPA/A/2000/004956A MXPA00004956A MXPA00004956A MX PA00004956 A MXPA00004956 A MX PA00004956A MX PA00004956 A MXPA00004956 A MX PA00004956A MX PA00004956 A MXPA00004956 A MX PA00004956A
- Authority
- MX
- Mexico
- Prior art keywords
- product
- procedure similar
- treat
- title compound
- mmol
- Prior art date
Links
- 150000002923 oximes Chemical class 0.000 title claims description 11
- 230000003042 antagnostic Effects 0.000 title description 9
- 239000005557 antagonist Substances 0.000 title description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 189
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 26
- 239000011780 sodium chloride Substances 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 5
- 239000000460 chlorine Substances 0.000 claims description 29
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 239000000047 product Substances 0.000 description 240
- 238000000034 method Methods 0.000 description 205
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 130
- 238000002360 preparation method Methods 0.000 description 98
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 96
- 239000000243 solution Substances 0.000 description 83
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 70
- 235000019439 ethyl acetate Nutrition 0.000 description 64
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 52
- 239000000203 mixture Substances 0.000 description 45
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 45
- 229910001868 water Inorganic materials 0.000 description 38
- 239000000741 silica gel Substances 0.000 description 37
- 229910002027 silica gel Inorganic materials 0.000 description 37
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 33
- 238000004587 chromatography analysis Methods 0.000 description 33
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 33
- 239000008079 hexane Substances 0.000 description 30
- 238000003756 stirring Methods 0.000 description 29
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 28
- 230000035693 Fab Effects 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 26
- 239000000284 extract Substances 0.000 description 25
- 239000012141 concentrate Substances 0.000 description 24
- 239000012044 organic layer Substances 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 150000001412 amines Chemical class 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 23
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- -1 N-substituted piperazinyl Chemical group 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- 239000003480 eluent Substances 0.000 description 19
- 239000003921 oil Substances 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 18
- 108010040722 Neurokinin-2 Receptors Proteins 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- 239000012043 crude product Substances 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- GGHLXLVPNZMBQR-UHFFFAOYSA-N 3,5-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC(Cl)=CC(Cl)=C1 GGHLXLVPNZMBQR-UHFFFAOYSA-N 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- MONMFXREYOKQTI-UHFFFAOYSA-M 2-bromopropanoate Chemical compound CC(Br)C([O-])=O MONMFXREYOKQTI-UHFFFAOYSA-M 0.000 description 9
- LKRMTUUCKBQGFO-UHFFFAOYSA-N N-phenylpiperidin-4-amine Chemical compound C1CNCCC1NC1=CC=CC=C1 LKRMTUUCKBQGFO-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 239000012267 brine Substances 0.000 description 9
- ZCSHNCUQKCANBX-UHFFFAOYSA-N Lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 8
- 239000011149 active material Substances 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 7
- 150000002576 ketones Chemical class 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Inorganic materials [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 6
- 239000007832 Na2SO4 Substances 0.000 description 6
- 108010040716 Neurokinin-3 Receptors Proteins 0.000 description 6
- 102000002003 Neurokinin-3 Receptors Human genes 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N t-BuOH Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- RHQDFWAXVIIEBN-UHFFFAOYSA-N 2,2,2-trifluoroethyl alcohol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 5
- 208000006673 Asthma Diseases 0.000 description 5
- 206010006482 Bronchospasm Diseases 0.000 description 5
- 102100020227 TACR2 Human genes 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 4
- KQKFQBTWXOGINC-UHFFFAOYSA-N 4-phenylpiperidin-4-ol Chemical compound C=1C=CC=CC=1C1(O)CCNCC1 KQKFQBTWXOGINC-UHFFFAOYSA-N 0.000 description 4
- 208000009079 Bronchial Spasm Diseases 0.000 description 4
- 206010064913 Bronchial disease Diseases 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 208000008665 Gastrointestinal Disease Diseases 0.000 description 4
- 229910004373 HOAc Inorganic materials 0.000 description 4
- 208000008085 Migraine Disorders Diseases 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 200000000018 inflammatory disease Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- VMBJJCDVORDOCF-UHFFFAOYSA-N prop-2-enyl 2-chloroacetate Chemical compound ClCC(=O)OCC=C VMBJJCDVORDOCF-UHFFFAOYSA-N 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000002829 reduced Effects 0.000 description 4
- 230000020341 sensory perception of pain Effects 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- QUKGLNCXGVWCJX-UHFFFAOYSA-N 1,3,4-thiadiazol-2-amine Chemical compound NC1=NN=CS1 QUKGLNCXGVWCJX-UHFFFAOYSA-N 0.000 description 3
- JBKINHFZTVLNEM-UHFFFAOYSA-N 2-bromoethoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCBr JBKINHFZTVLNEM-UHFFFAOYSA-N 0.000 description 3
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 3
- ZJIOBDJEKDUUCI-UHFFFAOYSA-N 3,5-dimethylbenzoyl chloride Chemical compound CC1=CC(C)=CC(C(Cl)=O)=C1 ZJIOBDJEKDUUCI-UHFFFAOYSA-N 0.000 description 3
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- 206010003246 Arthritis Diseases 0.000 description 3
- 210000003169 Central Nervous System Anatomy 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 206010011401 Crohn's disease Diseases 0.000 description 3
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 206010015037 Epilepsy Diseases 0.000 description 3
- 208000009745 Eye Disease Diseases 0.000 description 3
- 206010027599 Migraine Diseases 0.000 description 3
- 206010053643 Neurodegenerative disease Diseases 0.000 description 3
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 3
- 101710027499 Os03g0268000 Proteins 0.000 description 3
- VUVGYHUDAICLFK-UHFFFAOYSA-N Perosmic oxide Chemical compound O=[Os](=O)(=O)=O VUVGYHUDAICLFK-UHFFFAOYSA-N 0.000 description 3
- 206010061920 Psychotic disease Diseases 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N Sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- 101700065588 TAC1 Proteins 0.000 description 3
- 102100002996 TAC1 Human genes 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M Tetra-n-butylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 150000001350 alkyl halides Chemical class 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Chemical class NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 239000002740 neurokinin 3 receptor antagonist Substances 0.000 description 3
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- GINSRDSEEGBTJO-UHFFFAOYSA-N thietane 1-oxide Chemical compound O=S1CCC1 GINSRDSEEGBTJO-UHFFFAOYSA-N 0.000 description 3
- ADNPLDHMAVUMIW-CUZNLEPHSA-N (2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-N-[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-y Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- YUBDLZGUSSWQSS-UHFFFAOYSA-N 1-benzylpiperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=CC=C1 YUBDLZGUSSWQSS-UHFFFAOYSA-N 0.000 description 2
- ZOUPGSMSNQLUNW-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(Cl)C(Cl)=C1 ZOUPGSMSNQLUNW-UHFFFAOYSA-N 0.000 description 2
- ZGZMEKHQIZSZOH-UHFFFAOYSA-N 2-chloro-6-methylpyridine-4-carboxylic acid Chemical compound CC1=CC(C(O)=O)=CC(Cl)=N1 ZGZMEKHQIZSZOH-UHFFFAOYSA-N 0.000 description 2
- BUHYMJLFRZAFBF-UHFFFAOYSA-N 3,4,5-trimethoxybenzoyl chloride Chemical compound COC1=CC(C(Cl)=O)=CC(OC)=C1OC BUHYMJLFRZAFBF-UHFFFAOYSA-N 0.000 description 2
- QGMROEZDWJTIDW-UHFFFAOYSA-N 3-bromopropoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCCBr QGMROEZDWJTIDW-UHFFFAOYSA-N 0.000 description 2
- AMRZUHVOHXAKIW-UHFFFAOYSA-N 3-chloro-5-methylbenzoyl chloride Chemical compound CC1=CC(Cl)=CC(C(Cl)=O)=C1 AMRZUHVOHXAKIW-UHFFFAOYSA-N 0.000 description 2
- BHELZAPQIKSEDF-UHFFFAOYSA-N Allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 2
- DFNYGALUNNFWKJ-UHFFFAOYSA-N Aminoacetonitrile Chemical compound NCC#N DFNYGALUNNFWKJ-UHFFFAOYSA-N 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N Carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N Ethyl iodide Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- 102100018142 NDC1 Human genes 0.000 description 2
- 108060005239 NDC1 Proteins 0.000 description 2
- 102000009493 Neurokinin receptors Human genes 0.000 description 2
- 108050000302 Neurokinin receptors Proteins 0.000 description 2
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- JJHHIJFTHRNPIK-UHFFFAOYSA-N benzenesulfinylbenzene Chemical compound C=1C=CC=CC=1S(=O)C1=CC=CC=C1 JJHHIJFTHRNPIK-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229910052681 coesite Inorganic materials 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229910052906 cristobalite Inorganic materials 0.000 description 2
- YXHKONLOYHBTNS-UHFFFAOYSA-N diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 238000011068 load Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 229940113083 morpholine Drugs 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229910052904 quartz Inorganic materials 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- AGGHKNBCHLWKHY-UHFFFAOYSA-N sodium;triacetyloxyboron(1-) Chemical compound [Na+].CC(=O)O[B-](OC(C)=O)OC(C)=O AGGHKNBCHLWKHY-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229910052682 stishovite Inorganic materials 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 229910052905 tridymite Inorganic materials 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- PXJACNDVRNAFHD-UHFFFAOYSA-N (2-methoxyphenyl)methanamine Chemical compound COC1=CC=CC=C1CN PXJACNDVRNAFHD-UHFFFAOYSA-N 0.000 description 1
- HOBFSNNENNQQIU-SNVBAGLBSA-N (2R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-2-phenylacetic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)C1=CC=CC=C1 HOBFSNNENNQQIU-SNVBAGLBSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- HCUOEKSZWPGJIM-YBRHCDHNSA-N (E,2E)-2-hydroxyimino-6-methoxy-4-methyl-5-nitrohex-3-enamide Chemical compound COCC([N+]([O-])=O)\C(C)=C\C(=N/O)\C(N)=O HCUOEKSZWPGJIM-YBRHCDHNSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- IBLMYGXJKQIGSN-UHFFFAOYSA-N 1-(bromomethyl)-2,4-difluorobenzene Chemical compound FC1=CC=C(CBr)C(F)=C1 IBLMYGXJKQIGSN-UHFFFAOYSA-N 0.000 description 1
- CTJIGYSODYOMGI-UHFFFAOYSA-N 1-(bromomethyl)-3,5-dichlorobenzene Chemical compound ClC1=CC(Cl)=CC(CBr)=C1 CTJIGYSODYOMGI-UHFFFAOYSA-N 0.000 description 1
- HFTUZDNRTOTJCX-UHFFFAOYSA-N 1-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-(3,4-dichlorophenyl)-5-hydroxypentan-2-one Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(CCO)C(=O)COCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HFTUZDNRTOTJCX-UHFFFAOYSA-N 0.000 description 1
- MLEGMEBCXGDFQT-UHFFFAOYSA-N 1-benzylpiperidin-2-one Chemical compound O=C1CCCCN1CC1=CC=CC=C1 MLEGMEBCXGDFQT-UHFFFAOYSA-N 0.000 description 1
- ALAQDUSTXPEHMH-UHFFFAOYSA-N 1-bromo-2-methylsulfanylbenzene Chemical compound CSC1=CC=CC=C1Br ALAQDUSTXPEHMH-UHFFFAOYSA-N 0.000 description 1
- LOYZVRIHVZEDMW-UHFFFAOYSA-N 1-bromo-3-methylbut-2-ene Chemical compound CC(C)=CCBr LOYZVRIHVZEDMW-UHFFFAOYSA-N 0.000 description 1
- NKYFJZAKUPSUSH-UHFFFAOYSA-N 1-bromo-3-methylsulfanylbenzene Chemical compound CSC1=CC=CC(Br)=C1 NKYFJZAKUPSUSH-UHFFFAOYSA-N 0.000 description 1
- YEUYZNNBXLMFCW-UHFFFAOYSA-N 1-bromo-4-methylsulfanylbenzene Chemical compound CSC1=CC=C(Br)C=C1 YEUYZNNBXLMFCW-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-Trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- XNICZRGXAXLQTF-UHFFFAOYSA-N 2-(dimethylamino)-6-methylpyridine-4-carboxylic acid Chemical group CN(C)C1=CC(C(O)=O)=CC(C)=N1 XNICZRGXAXLQTF-UHFFFAOYSA-N 0.000 description 1
- YZPCLGACDQOQEN-UHFFFAOYSA-N 2-[(3,5-dichlorobenzoyl)-ethylamino]acetic acid Chemical compound OC(=O)CN(CC)C(=O)C1=CC(Cl)=CC(Cl)=C1 YZPCLGACDQOQEN-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- HVFQJWGYVXKLTE-UHFFFAOYSA-N 3,5-bis(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HVFQJWGYVXKLTE-UHFFFAOYSA-N 0.000 description 1
- HOQDXNMVZFRKAQ-UHFFFAOYSA-N 3,5-dimethoxy-4-methylbenzoyl chloride Chemical compound COC1=CC(C(Cl)=O)=CC(OC)=C1C HOQDXNMVZFRKAQ-UHFFFAOYSA-N 0.000 description 1
- GETHXZBPJVUSBH-UHFFFAOYSA-N 4-(2-methylsulfinylphenyl)piperidine Chemical compound CS(=O)C1=CC=CC=C1C1CCNCC1 GETHXZBPJVUSBH-UHFFFAOYSA-N 0.000 description 1
- OQMOVLOOIDNTQX-UHFFFAOYSA-N 4-(3-bromopropyl)isoindole-1,3-dione Chemical compound BrCCCC1=CC=CC2=C1C(=O)NC2=O OQMOVLOOIDNTQX-UHFFFAOYSA-N 0.000 description 1
- UTFCUGLGVGSABG-UHFFFAOYSA-N 4-(4-methylsulfonylphenyl)piperidine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1CCNCC1 UTFCUGLGVGSABG-UHFFFAOYSA-N 0.000 description 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-Hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- UTBULQCHEUWJNV-UHFFFAOYSA-N 4-Phenylpiperidine Chemical compound C1CNCCC1C1=CC=CC=C1 UTBULQCHEUWJNV-UHFFFAOYSA-N 0.000 description 1
- CDIIZULDSLKBKV-UHFFFAOYSA-N 4-chlorobutanoyl chloride Chemical compound ClCCCC(Cl)=O CDIIZULDSLKBKV-UHFFFAOYSA-N 0.000 description 1
- DMCVVFIWYIKAEJ-UHFFFAOYSA-N 4-phenylpiperidine-4-carbonitrile Chemical compound C=1C=CC=CC=1C1(C#N)CCNCC1 DMCVVFIWYIKAEJ-UHFFFAOYSA-N 0.000 description 1
- SVNNWKWHLOJLOK-UHFFFAOYSA-N 5-chloropentanoyl chloride Chemical compound ClCCCCC(Cl)=O SVNNWKWHLOJLOK-UHFFFAOYSA-N 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N Adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- RAIPHJJURHTUIC-UHFFFAOYSA-N Aminothiazole Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N Benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N Benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N Benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
- FTQIIZDSEYXUCH-UHFFFAOYSA-N BrCC(C(C(C)(C)C)(O[SiH3])C)C Chemical compound BrCC(C(C(C)(C)C)(O[SiH3])C)C FTQIIZDSEYXUCH-UHFFFAOYSA-N 0.000 description 1
- MUXHSUUSKXITHK-UHFFFAOYSA-N CCCO.NC(N)=O Chemical compound CCCO.NC(N)=O MUXHSUUSKXITHK-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FFHWGQQFANVOHV-UHFFFAOYSA-N Dimethyldioxirane Chemical compound CC1(C)OO1 FFHWGQQFANVOHV-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 1
- PYPOUOFMOWRCGP-UHFFFAOYSA-N I[NH-] Chemical compound I[NH-] PYPOUOFMOWRCGP-UHFFFAOYSA-N 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N Lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- HHVIBTZHLRERCL-UHFFFAOYSA-N Methylsulfonylmethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 1
- 210000003097 Mucus Anatomy 0.000 description 1
- 229910004008 NLi Inorganic materials 0.000 description 1
- 101700000225 NR4A3 Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- KPTCZURLWZSRKB-UHFFFAOYSA-N O-prop-2-enylhydroxylamine Chemical compound NOCC=C KPTCZURLWZSRKB-UHFFFAOYSA-N 0.000 description 1
- 102100001666 OSCP1 Human genes 0.000 description 1
- 101700064966 OSCP1 Proteins 0.000 description 1
- 101710013972 PLSCR1 Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N Potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N Potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N Propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 229910019020 PtO2 Inorganic materials 0.000 description 1
- 101710030983 RNF138 Proteins 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 101700036345 SGE1 Proteins 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M Sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 102100020224 TACR3 Human genes 0.000 description 1
- 101710026034 TACR3 Proteins 0.000 description 1
- 101710029702 TICAM1 Proteins 0.000 description 1
- 101710021425 TRIM69 Proteins 0.000 description 1
- 102100003447 TRIM69 Human genes 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N Thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 229910003074 TiCl4 Inorganic materials 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J Titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 210000003437 Trachea Anatomy 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N Trifluoromethanesulfonic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- DHVHORCFFOSRBP-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 DHVHORCFFOSRBP-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000005262 alkoxyamine group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000003975 aryl alkyl amines Chemical class 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 239000008228 bacteriostatic water for injection Substances 0.000 description 1
- PFQULFAWUPNOEZ-UHFFFAOYSA-N benzyl 4-(2-methylthiophen-3-yl)piperidine-1-carboxylate Chemical compound S1C=CC(C2CCN(CC2)C(=O)OCC=2C=CC=CC=2)=C1C PFQULFAWUPNOEZ-UHFFFAOYSA-N 0.000 description 1
- MTFKRNPSAAULFH-UHFFFAOYSA-N benzyl 4-hydroxy-4-(2-methylthiophen-3-yl)piperidine-1-carboxylate Chemical compound S1C=CC(C2(O)CCN(CC2)C(=O)OCC=2C=CC=CC=2)=C1C MTFKRNPSAAULFH-UHFFFAOYSA-N 0.000 description 1
- VZOVOHRDLOYBJX-UHFFFAOYSA-N benzyl 4-oxopiperidine-1-carboxylate Chemical compound C1CC(=O)CCN1C(=O)OCC1=CC=CC=C1 VZOVOHRDLOYBJX-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- 230000003435 bronchoconstrictive Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 238000005828 desilylation reaction Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- RNJOKCPFLQMDEC-UHFFFAOYSA-N dimethyl 3-oxopentanedioate Chemical compound COC(=O)CC(=O)CC(=O)OC RNJOKCPFLQMDEC-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- KLGZELKXQMTEMM-UHFFFAOYSA-N hydride Chemical compound [H-] KLGZELKXQMTEMM-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;O-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- XIQUJVRFXPBMHS-UHFFFAOYSA-N hydron;O-prop-2-enylhydroxylamine;chloride Chemical compound Cl.NOCC=C XIQUJVRFXPBMHS-UHFFFAOYSA-N 0.000 description 1
- HQZMRJBVCVYVQA-UHFFFAOYSA-N hydron;methyl 2-(methylamino)acetate;chloride Chemical compound Cl.CNCC(=O)OC HQZMRJBVCVYVQA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- VXGABWCSZZWXPC-UHFFFAOYSA-N methyl 2-(methylamino)acetate Chemical compound CNCC(=O)OC VXGABWCSZZWXPC-UHFFFAOYSA-N 0.000 description 1
- SRXOJMOGPYFZKC-UHFFFAOYSA-N methyl 4-chloro-4-oxobutanoate Chemical compound COC(=O)CCC(Cl)=O SRXOJMOGPYFZKC-UHFFFAOYSA-N 0.000 description 1
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N methyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001979 organolithium group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000005545 phthalimidyl group Chemical group 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- GJQNVZVOTKFLIU-UHFFFAOYSA-N piperidin-1-ium-4-one;chloride Chemical compound Cl.O=C1CCNCC1 GJQNVZVOTKFLIU-UHFFFAOYSA-N 0.000 description 1
- LTEKQAPRXFBRNN-UHFFFAOYSA-N piperidin-4-ylmethanamine Chemical compound NCC1CCNCC1 LTEKQAPRXFBRNN-UHFFFAOYSA-N 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 150000003378 silver Chemical class 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000002462 tachykinin receptor antagonist Substances 0.000 description 1
- KLKBCNDBOVRQIJ-UHFFFAOYSA-N tert-butyl 4-(aminomethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CN)CC1 KLKBCNDBOVRQIJ-UHFFFAOYSA-N 0.000 description 1
- ZDEWFVGYYNGCSI-UHFFFAOYSA-N tert-butyl 4-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)CC1CCN(C(=O)OC(C)(C)C)CC1 ZDEWFVGYYNGCSI-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BXYXWBBROYOLIG-UHFFFAOYSA-N tert-butyl-ethoxy-dimethylsilane Chemical compound CCO[Si](C)(C)C(C)(C)C BXYXWBBROYOLIG-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- BBUQUBATODVRRV-UHFFFAOYSA-N triacetyloxyboron(1-) Chemical compound CC(=O)O[B-](OC(C)=O)OC(C)=O BBUQUBATODVRRV-UHFFFAOYSA-N 0.000 description 1
- PTMFUWGXPRYYMC-UHFFFAOYSA-N triethylazanium;formate Chemical compound OC=O.CCN(CC)CC PTMFUWGXPRYYMC-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Abstract
Compounds within the genus represented by structural formula (I) or a pharmaceutically acceptable salt thereof, wherein:T is substituted phenyl or substituted pyridyl;R1 is H, methyl, ethyl, -CH2CN, -CH2C(O)NH2, -(CH2)3SO3H, -CH2C(O)NHCH3, -CH2C(O)NHOH, -CH2C(O)NHOCH3, -CH2C(O)NHCH2CN, -CH2F, -CH2C(O)NHCH2SO3H, (a), (b), (c), (d) or (e);R4 is methyl or ethyl;and Z is substituted piperidinyl.
Description
QXIMAS SUBSTITUTED AS ANTAGONISTS IN NEUROQUININE
BACKGROUND OF THE INVENTION
The present invention relates to a genus of substituted oximes useful as tachykinin receptor antagonists, in particular as neuropeptide antagonists neurokinin-1 receptor (NK-?) And / or neurokinin-2 receptor (NK2) and / or Neurokinin-3 receptor (NK3). Neurokinin receptors are found in the nervous system and in the circulatory system and peripheral tissues of mammals and are therefore involved in a variety of biological processes. Accordingly, neurokinin receptor antagonists are expected to be useful in the treatment or prevention of various diseases of mammals, for example asthma, cough, chronic obstructive pulmonary diseases (COPD), bronchospasm, emesis, neurodegenerative diseases, eye diseases, inflammatory diseases. such as arthritis, central nervous system conditions such as migraines and epilepsy, nociception, psychosis and various gastrointestinal disorders such as Crohn's disease. In particular, it has been reported that NKi receptors are involved in microvascular leakage and mucosal secretion, and NK2 receptors have been associated with smooth muscle contraction, which makes the NKi and NK2 receptor antagonists especially useful in the treatment and prevention of asthma. The NKi and NK2 receptor antagonists have been previously described: the arylalkylamines were described in U.S. Patent No. 5,350,852, issued September 27, 1994, and the spiro-substituted azacycles were described in WO 94/29309, published on 22 December 1994. U.S. Patent No. 5,696,267 describes compounds represented by the generic structure
or a pharmaceutically acceptable salt thereof, wherein: a is 0, 1, 2 or 3; R is H, C -? - 6 alkyl, -OH or C2-C6 hydroxyalkyl; A is an optionally substituted oxime, hydrazine or olefin; X is a bond, -C (O) -, -O-, NR6 -, - S (O) e-, N (R6) C (O) -, -C (O) N (R6) -, -OC (O) NR6-, -OC (= S) NR6, -N (R6) C (= S) O-, -C (= NOR1) -, -S (O) 2N (R6) -, -N (R6) ) S (O) 2- N (R6) C (O) O- or -OC (O) -; b, d and e are independently 0, 1 or 2; T is H, phthalimidyl, aryl, heterocycloalkyl, heteroaryl, cycloalkyl or bridged cycloalkyl;
Q is -SR6, -N (R6) R7), -OR6, phenyl, naphthyl or heteroaryl; R6a, R7a, R8a, R9a R6 and R7 are H, C1-6 alkyl, C2-C6 hydroxyalkyl, Ci-C17 alky1 Ci-Cß alkoxy, phenyl or benzyl; or R6 and R7, together with the nitrogen to which they are attached, form a ring; R9a is R6 or -OR6; Z is morpholinyl, optionally N-substituted piperazinyl, optionally
Substituted g is 0-3 and h is 1-4, with the proviso that the sum of h and g is
1-7; wherein the aryl, heterocycloalkyl, heteroaryl, cycloalkyl and bridged cycloalkyl groups are optionally substituted. It has been found that some compounds within this generic structure show surprisingly higher activity as neurokinin antagonists than those previously described in specific form.
BRIEF DESCRIPTION OF THE INVENTION
The compounds of the present invention are represented by the formula or by a pharmaceutically acceptable salt thereof, wherein: T is R2-phenyl or R3-pyridyl; R1 is H, methyl, ethyl, -CH2CN, -CH2C (O) NH2, - (CH2) 3SO3H, CH2C (O) NHCH3, -CH2C (O) NHOH, -CH2C (O) NHOCH3, -CH2C (O) NHCH2CN , CH2F, -CH2C (O) NHCH2SO3H,
R represents 2-3 substituents independently selected from the group consisting of chlorine, methyl and methoxy; R3 represents 2 to 3 substituents independently selected from the group consisting of chlorine and methyl; R 4 is methyl or ethyl; and Z is
Z-isomers of the compounds of formula I are preferred. Compounds of formula I in which T is R2-phenyl are preferred, with compounds wherein R2 represents two chloro substituents, two methyl substituents (preferably 3,5-dichloro or 3,5-dimethyl), or two methoxy substituents and one methyl substituent (ie, 3,5-methoxy-4-methyl) considered to be the most preferred; especially preferred are compounds in which R2 represents two chloro groups. Also preferred are compounds of formula I in which R1 is methyl -CH2F, -CH2CN, - (CH2) 3SO3H, with methyl being most preferred. R 4 is preferably methyl. Another group of preferred compounds is one in which Z is
with
preferring
even more preferred, especially preferred. This invention also relates to the use of a compound of formula I in the treatment of asthma, cough, chronic obstructive pulmonary diseases (COPD), bronchospasm, emesis, neurodegenerative diseases, eye diseases, inflammatory diseases such as arthritis, central nervous system conditions such as migraine and epilepsy, nociception, psychosis, and various gastrointestinal disorders such as Crohn's disease. In another aspect, the invention relates to a pharmaceutical composition comprising a compound of formula I in a pharmaceutically acceptable carrier. The invention also relates to the use of said pharmaceutical composition in the treatment of asthma, cough, chronic obstructive pulmonary diseases (COPD), bronchospasm, emesis, neurodegenerative diseases, eye diseases, inflammatory diseases such as arthritis, central nervous system conditions such as migraine and epilepsy, nociception, psychosis, and various gastrointestinal disorders such as Crohn's disease.
DETAILED DESCRIPTION OF THE INVENTION
In the structural formulas that are shown throughout the specification and claims the hydrogen atoms can be understood, for example, the partial structure.
ap Some formulas can include a methyl group shown as a line and the point of adhesion to the other atom is shown as a line through which a wavy line is drawn, ie
The compounds of formula I can have at least one asymmetric carbon atom and all isomers, including the diastereomers, enantiomers and rotational isomers as well as the E and Z isomers of the oxime, hydrazone and olefin groups, are contemplated as part of this invention. The invention includes the isomers d and I both in pure form and in mixture, including racemic mixtures. The isomers can be prepared using conventional techniques, either by reaction of optically pure or optically enriched materials or by separation of the isomers of a compound of formula I. Those skilled in the art will appreciate that for some compounds of formula I, an isomer will show an pharmacological activity superior to that of the other isomers. The compounds of the invention have at least one amino group which can form pharmaceutically acceptable salts with organic and inorganic acids. Examples of suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, citric acetic, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, tartaric, methanesulfonic and other mineral and carboxylic acids which are well known for those skilled in the art. The salt is prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt. The free base form can be regenerated by treating the salt with a dilute aqueous base solution such as dilute aqueous sodium bicarbonate. The free base form differs from its respective salt form in some way with respect to some physical properties such as solubility in polar solvents, but on the other hand the salt is equivalent to its respective free base forms for the purposes of invention.
Some compounds of the invention are acids (for example, those compounds that possess a carboxyl group). These compounds form pharmaceutically acceptable salts with inorganic and organic bases. Examples of said salts are sodium, potassium, calcium aluminum, gold and silver salts. Also included are salts formed with pharmaceutically acceptable amines such as ammonia, alkylamines, hydroxyalkylamines, N-methylglucamine, and the like. The compounds of formula I can be prepared using methods that are well known to those skilled in the art for example by methods described in WO 96/34857. Those skilled in the art will recognize that other procedures may be applied, and that the process can be conveniently modified to prepare other compounds within the scope of formula I. The compounds of formula I defined above can be prepared as shown in the following reaction scheme related to the broader scope of the compounds which are described in WO 96/34857. In the reaction scheme, the variables are as defined above for the PCT application:
Stage 1 :
46 (A: R '21: alkoxy B: R21 = Cl C: R21 = -N (CH3) OCH3)
In step 1, a compound of formula 47A is reacted, where Q is as defined above, with a base such lithium diisopropylamide (LDA), KHMDS or KH in an inert organic solvent such as THF or DME for generate a dianion. An acid chloride, an ester or an amide of formula 46A, 46B, or 46C is added to obtain the ketone of formula 48. Preferably the reaction temperatures are between -78 ° C to 30 ° C. Alternatively, compounds of formula 48 can be generated by the reaction of a compound of formula 46, preferably 46C, with a metallized species of formula QCH2Mt in which Mt is a metal, such as lithium or MgHal, where "Hal" is halogen. Metallized species QCH2Mt can be generated by conventional methods, such as the treatment of compounds of formula QCH2Hal with Mg or by treating QCH3 with an organolithium base.
Stage 2:
49
In step 2, for the compounds described in the PCT application where R is not hydrogen, the ketone 48 is reacted with an appropriate base, such as LDA or KH in an inert organic solvent such as THF. For compounds wherein R is alkyl or hydroxyalkyl, a compound R-R17 ', wherein R17' is a leaving group such as Br, I or triflate. For compounds of the PCT application where R is OH, an appropriate oxidizing agent such as dimethyldioxirane or a Davis reagent is added. Preferred reaction temperatures are between -78 ° C to 50 ° C. For the compounds of the present invention, which correspond to the compounds of the PCT application, in which R is H, the ketone 48 is used directly in step 3.
Stage 3:
In step 3, the ketone 49 is reacted with a base such as LDA in a solvent such as THF, and then an olefin of formula 50 is added, where R17"is as previously defined, to obtain the adduct 51 The preferred reaction temperatures are between -78 ° C to 60 ° C.
Stage 4:
In step 4, the ketone 5_1 is reacted with HA ', where A' is NH-OR1, in an organic solvent such as pyridine or ethanol at a temperature between 25 ° C to 150 ° C to obtain a compound of formula 52 .
Stage 5:
In step 5, a compound of formula 52 is oxidized by ozonophosis to obtain an aldehyde of formula 53. Suitable organic solvents include EtOAc, CH 3 OH, ethanol, CH 2 Cl 2 or the like. Preferred reaction temperatures are -78 to 0 ° C.
Stage 6:
In step 6, an aldehyde of formula 53 is reacted with a compound of formula Z-H, wherein Z is as previously defined. The reaction is preferably carried out with a suitably substituted amine (such as its acid salt, for example, HCl or maleate or as its free base) and a hydride source such as NaBH 3 CN or sodium triacetoxyborohydride in an appropriate solvent (for example CH3OH, CH3CH2OH, or CF3CH2OH for NaBH3CN, or THF, 1,2-dichloroethane, CH3CN or CF3CH2OH for triacetoxyborohydride), with 3A sieves to obtain the desired product. Any suitable temperature can be used, with temperatures between 0 ° C and 25 ° C being preferred. Alternatively, a compound of formula I can be prepared from 51 by the following reaction scheme, wherein the variables are as defined for the cited PCT application.
Compound 51 is oxidized to a compound of formula 54 under conditions similar to those described for the preceding step 5. The aldehyde of formula 54 is reacted with a compound of formula ZH in a manner similar to that described in step 6 and the resulting ketone is then reacted with a compound of formula HA 'as described above in step 4 for obtaining the compound of formula I. Reactive groups not involved in the preceding processes can be protected during reactions with conventional protecting groups which can be removed by conventional procedures after the reaction. Table 1 below shows some typical protective groups:
TABLE I
The compounds of formula I proved to be antagonists of the NK- ?, and / or NK2, and / or NK3 receptors, and therefore, are useful for treating conditions caused or aggravated by the stimulation of said receptors. The present invention also relates to a pharmaceutical composition comprising a compound of formula I and a pharmaceutically acceptable carrier. The compounds of this invention can be administered in conventional oral dosage form such as capsules, tablets, powders, seals, suspensions or solutions or in injectable dosage form such as solutions, suspensions, or powders to be reconstituted. The pharmaceutical compositions can be prepared with conventional excipients and additives, using well-known pharmaceutical formulation techniques. The pharmaceutically acceptable excipients and additives include non-toxic, chemically compatible fillers, binders, disintegrants, buffers, preservatives, anti-oxidants, lubricants, flavors, thickeners, coloring agents, emulsifiers and the like. The daily dose of a compound of formula I for the treatment of asthma, cough, bronchospasm, inflammatory diseases, migraine, nociception and gastrointestinal disorders is from about 0.1 mg to about 20 mg / kg of body weight per day, preferably about 0.5. up to about 15 mg / kg. For an average body weight of 70 kg, the dosage range will therefore be from about 1 to about 1500 mg of drug per day, preferably about 50 to about 200 mg, and more preferably about 50 to about 500 mg / kg per day , administered in a single dose or in 2-4 divided doses. The exact dose, however, will be determined by the clinician and will depend on the potency of the compound administered, the age, weight, state and response of the patient. Examples are given below for preparing starting materials and compounds of formula I. As used herein, Me is methyl, Bu is butyl, Br is bromine, Ac is acetyl, Et is ethyl and Ph is phenyl.
PREPARATION 1 1-rr (3,5-bisftrifluoromethanophenimethoxy-3- (3,4-dichlorophenyl) -5- (4-hydroxy-4-phenyl-1-piperidinyl) -2-pentanone
A solution of (c / s) -lll (3,5-bis (trifluoromethyl) phenyl] methoxy] methyl] -4- (3,4-dichlorophenyl) -4-hydroxy-4-phenol-1 is treated. -piperidinebutanol (2.0 g, 3.08 mmol) in acetone (90 ml, 0 ° C () with Jones's reagent (9 ml of H2CrO in H2SO (ca.8M).) The orange-colored suspension is stirred at 0 ° C. for 1 hour, and then divided between CH2Cl2 (150 ml) and saturated aqueous NaHCO3 (150 ml) The aqueous layers are extracted with CH2Cl2 (3 x 150 ml) and the combined organic layers are extracted again with saturated aqueous NaHC3. (150 ml), dried (Na2SO) and concentrated to give 1.94 g of crude product, purified by chromatography on silica gel (column: 4 cm x 15 cm, eluent: EtOAc: hexane: triethylamine (66:33: 2)) to obtain 1.64 g (2.53 mmol, 82%) of the title compound as a colorless foam HRMS (FAB, M + H +): m / e calculated for [C3? H3oNO3CI2F6] +: 648.1507, found 648.1496 .
PREPARATION 2
Step 1: Dissolve 4-aminomethyl-piperidine (30.00 g, 0.263 mol) in CH3OH (500 ml), cool to -30 ° C under N2, add di-t-butyl dicarbonate (38.23 g, 0.175 mol) in CH3OH (100 ml) dropwise, warm slowly to 23 ° C and stir for 16 hours. Concentrate, add CH2CI2 (700 mL), wash with saturated aqueous NaCl (2x200 mL), dry the organic solution (MgSO4), filter and concentrate to give 36.80 g of an 86:14 mixture of the title compound. and 4 - [(1,1-dimethylethyloxycarbonyl) methyl] -1-piperidinecarboxylate 1,1-dimethylethyl ester.
Step 2A: Dissolve the product (19.64 g, 0.0916 moles, 22.84 g of the mixture) from step 1 in dry CH2Cl2 (350 ml) and cool to 0 ° C under N2. Pyridine (10.87 g, 11.1 ml, 0.137 mol) is added, then chlorovaleryl chloride
(15.63 g, 13.0 ml, 0.101 moles), is slowly heated to 23 ° C and stirred for 16 hours. Saturated aqueous NH4C (300 mL) is added, the layers separated and extracted with CH2Cl2 (2x250 mL). The combined organic extracts are dried (MgSO4), filtered and concentrated. Purify by chromatography (1000 ml of evaporative silica gel: eluent: 1: 1 EtOAc: hexane, then EtOAc): The appropriate fractions are combined and concentrated to give 25.36 g (0.0762 moles, 84%) as an oil colorless MS (CICH4): m / e 333 (M + 1).
Step 2B: Treat the product of step 1 in a procedure similar to that described for step 2A, using chlorobutyryl chloride. MS (FAB); m / e 319 (M + 1).
Stage 3
PREPARATION 2A
Wash NaH (3.84 g, 0.160 moles, 6.40 g of 60% by weight) with hexane (25 ml), suspend in dry THF (150 ml) and cool to 0 ° C under N2. The product (25.35 g, 0.0762 mol) from step 2A in dry THF (150 ml) is added dropwise. It is stirred at 23 ° C for 30 minutes, refluxed for 6 hours, and stirred at 23 ° C for 16 hours. Cool to 0 ° C and add water (150 ml) and 1N HCl (150 ml). Concentrate and extract with EtOAc (3x200 ml). The combined organic extracts are washed with saturated aqueous NaCl, dried (MgSO4), filtered and concentrated. Purify by chromatography (600 ml of evaporative silica gel); eluent: 5% CH3OH-CH2Cl2). The appropriate fractions are combined and concentrated to give 21.62 g (0.0729 mol, 96%) of the title compound as a yellow oil. MS (FAB): m / e 297 (M + 1).
PREPARATION 2B
The product of step 2B is treated in a procedure similar to that described for prep. 2A. MS (FAB): m / e 283 (m + 1).
PREPARATION 2C
The product (1.50 g, 5.06 mmol) of the prep is combined. 2A and Lawesson's reagent (1.13 g 2.78 mmoles) in dry THF (20 ml) under N2. Stir at 23 ° C for 20 hours. Concentrate and purify by chromatography (200 ml of evaporative silica gel: eluent 1: 3 EtOAc: hexane, 1: 2 EtOAc: hexane, and then 1: 1 EtOAc: hexane). The appropriate fractions are combined and concentrated to give 1.30 g (4.16 mmol, 82%) as a green oil. MS (FAB): m / e 313 (M + 1).
PREPARATION 2D
Dissolve the product (2.50 g, 8.43 mmol) of the prep, 2A in dry THF (30 mL), add borane-DMS (16.9 mL of 2.0 M in THF, 33.74 mmol) and reflux for 20 hours. Cool to 0 ° C and add CH3OH (20 mL). Concentrate, add EtOH (50 mL) and K2CO3 (4.66 g, 33.74 mmol). It is refluxed for 4 hours and cooled to 23 ° C. Water (100 ml) is added, it is concentrated and extracted with CH? C (4x50 ml). The combined organic extracts are dried (MgSO4), filtered and concentrated. They are purified by chromatography (200 ml of evaporative silica gel, eluent: 7% CH3OH-CH2Cl2). Appropriate fractions are combined and concentrated to give 1.72 g (6.09 mmol, 72%) of the title compound as a colorless oil. MS (FAB): m / e 283 (m + 1).
PREPARATION 2E
Dissolve the product (1.50 g, 5.06 mmol) of the prep. 2A in dry THF (20 ml) and cooled to -78 ° C under N2. Add [(CH3) 3S] 2NLi (5.5 mL of 1.0 M in THF, 5.5 mmol) and stir at -78 ° C for 1 hour. Add bromomethylcyclopropane (0.820 g, 0.59 ml, 6.07 mmol), heat slowly to 23 ° C and stir for 16 hours, add saturated aqueous NH4CI (40 ml), extract with EtOAc (3x30 ml), wash the Organic extracts combined with saturated aqueous NaCl, dried (MgSO4), filtered and concentrated. Purify by chromatography (175 ml of evaporative silica gel, eluent: 2% CH3OH-CH2CI2 and then 4% CH3OH-CH2Cl2.) Combine the appropriate fractions and concentrate to give 0.93 g (2.65 mmol, 53%) of the Compound title in the form of a colorless oil, MS (FAB): m / e 351 (M + 1).
PREPARACON 2F
It is the product of prep. 2A in a procedure similar to that described for prep. 2E, using allyl bromide. MS (CI / CH4): m / e 337 (M + 1).
Stage 4: The prep products are dissolved separately. 2 A to 2F in CH 2 Cl 2, add trifluoroacetic acid and stir at 23 ° C for 4 hours. Concentrate, add 1 N NaOH, extract with CH 2 Cl 2, dry the combined organic extracts (MgSO 4), filter and concentrate to obtain the corresponding substituted piperidines.
PREPARATION 3
Step 1: Using the procedures of Preparation 2, replace 4-aminomethyl-1- (1,1-dimethylethyloxycarbonyl) -piperidine with 4-amino-1-benzylpiperidine in prep. 2, stage 2A and continue through prep. 2, stage 3.
Step 2: Treat the palladium hydroxide (2.0 g) in EtOAc (100 ml) with the product of step 1 (25.0 g, 0.0918 mol) in EtOAc (200 ml) and (tBOC) 2O in EtOAc (200 ml) . To prepare, the resulting mixture is stirred on a Parr stirrer at 50 psi H2 pressure for 3 hours and then more palladium hydroxide catalyst (2 g) is added and stirred for 16 hours. The catalyst is removed by filtration and washed with EtOAc. Concentrate and purify by chromatography (silica gel, eluent 5% CH3OH-CH2Cl2). The appropriate fractions are combined and concentrated to give 24.37 g of the product as a white solid. MS (FAB): m / e 283 (M + 1).
Step 3: Treat the product of Step 2 according to a procedure similar to that described for preparation 2F. MS (CI / CH4): m / e 267 (M-55).
Step 4A: Treat the product of step 3 (5.17 g, 16.0 mmol) in EtOAc (90 ml) and H20 (90 ml) with Nal04 (20.57 g, 96.2 mmol) and Ru02 (0.064 g, 0.48 mmol). Stir at 23 ° C for 5 hours, add 1 N HCl (20 mL) and filter. The solid is washed with EtOAc and H2O. The filter layers are separated and extracted with EtOAc. The combined organic extracts are dried (MgSO), passed through charcoal and concentrated to give 5.10 g of the title compound. MS (FAB): m / e 341 (M + 1).
Step 4B Treat the product of preparation 2F according to a procedure similar to that described in step 4A to give the protected amino acid.
Step 5A: The substituted piperazines 3A5 to 3H5 as well as the 3N5 and 305 are prepared in a similar procedure using the appropriate amine. Treat the product of step 4A (1.00 g 2.94 mmole) in CH2Cl2 (20 ml) with carbonyldiimidazole (0.57 g, 3.53 mmol) and stir at 23 ° C for 4 hours. The appropriate amine is added and stirred for 16 hours. Add 1N HCl and extract with CH2Cl2. The combined organic extracts are dried (MgSO 4), filtered and concentrated. Purify by chromatography (silica gel: eluent: CH 3 -OH-CH 2 Cl 2). Appropriate fractions are combined and concentrated to give 3A5 to 3H5 and 3N5-3O5.
Step 5B Compounds 3I5 to 3K5 were prepared in a procedure similar to that described in step 5A by substituting the product from step 4A for the product of step 4B using the appropriate amine.
PREPARATION 3L5
The product of preparation 3, step 2 is treated according to the procedure similar to that described in preparation 2F, substituting the allyl bromide for the product of example 18L, step 2, to obtain the title compound.
Step 6 Compounds 3A6 to 3N6 are prepared by treating products 3A5 to 305 (step 5) according to the procedure similar to prep. 2, step 4. The preparation of 306 is carried out by treating the product of preparation 3, step 1, according to a procedure similar to that described for preparation 3, step 2, omitting (t-BOC) 2? to obtain the title compound. PREPARATION 4
PREPARATION 4A
Step 1 Treat N-benzyl-piperidone (8.00 g, 0.0423 mol) in CH2Cl2 with (CH3) 3 SiCN (4.82 g, 0.0486 mol) and Znl2 (0.68 g, 0.0021 mol). It is stirred at 23 ° C for 16 hours and concentrated. Add saturated CH3OH NH3 (30 mL) and heat to 40 ° C. The resulting mixture is concentrated, CH2Cl2 (200 ml) is added, dried (MgSO4), filtered and concentrated to give 11.06 g of the desired product as a yellow oil. MS (CI / CH4): m / e 189 (M-26).
Step 2: Treat the product of step 1 according to a procedure similar to that of preparation 2, steps 2A and 3. EM (CI / CH). m / e 298 (M + 1).
Step 3: Treat the product from step 2 (1.50 g, 5.04 mmol) in t-BuOH (25 mL) with KOH (0.99 g, 17.64 mmol) and reflux for 30 minutes. It is cooled to 23 ° C and concentrated. Saturated NaCl (40 mL) is added, extracted with CH2Cl2 (3x40 mL), dried (MgSO4), filtered and concentrated. Purify by evaporative chromatography (silica gel, eluent: 10% CH3OH-CH2Cl2). The appropriate fractions were combined and concentrated to give 0.98 g of the desired product as a yellow solid. P.f. = 184-186 ° C. MS (FAB): m / e 298 (M-17).
Step 4: Treat the product of step 3 (0.97 g, 3.08 mmol) in CH3OH (25 ml) with palladium hydroxide (0.40 g). Stir on a Parr shaker at 50 psi under H2 pressure for 16 hours. Filter, wash with CH3OH and concentrate to give 0.69 g of the title compound as a white solid. P.f. = 180-185 ° C. MS (FAB): m / e 210 (M-15)
PREPARATION 4B
Step 1 Treat the product of the present preparation 4A, step 2 (1.50 g, 5.04 mmol) in CH2Cl2 (25 ml) with trichloroethyl chloroformate (TROC-CI) (1.39 g, 6.55 mmol). Stir at 23 ° C for 16 hours. Add 0.25 N NaOH (40 mL), extract with CH2Cl2 (3x40 mL), dry (MgSO4), filter and concentrate. Purify by evaporative chromatography (silica gel, eluent: 1: 1 EtOAc: hexane to 2: 1 EtOAc: hexane). Appropriate fractions are combined and concentrated to give 1.31 g of the desired compound as a white solid P.f. = 185-186 ° C, MS (CI / CH4): m / e 382 (M + 1).
Step 2 Treat the product of step 1 (1.30 g, 3.40 mmol) in THF (20 ml) with HOAc (1.9 ml, 34.0 mmol) and zinc (2.22 g, 34.0 mmol). Stir at 23 ° C for 18 hours. H2O (10 mL) is added, filtered and washed with EtOAc. 6.25 N NaOH is added to the filtrate, extracted with CH2Cl2, dried (MgSO4), filtered and concentrated to give 0.70 g of the title compound as a white solid. MS (CI / CH4): m / e 208. (M + 1).
PREPARATION 4C
Step 1 Treat 4-cyano-4-phenylpiperidine in CH3OH with 50% KOH / H2O and heat in a sealed tube at 180 ° C for 2 hours. It is cooled to 23 ° C and concentrated to give the desired compound.
Step 2 Treat the product of step 1 with di-t-butyl-dicarbonate according to a procedure similar to that of preparation 2 step 1 to give the protected amino acid.
Step 3 The product of step 2 is coupled with morpholine according to a procedure similar to example 8 using DMF as a solvent.
Step 4 The amine is deprotected using a procedure similar to preparation 2, step 4, optionally substituting TFA for HCl
4D PREPARATION
Step 1: Acetaldehyde (4.6 g, 105 mmol) and dimethylacetone dicarboxylate (7.1 g, 35 mmol) were cooled to 0 ° C and treated with benzylamine (5.2 g, 49 mmol), 12 N HCl, (4.1 mL), and H2O (3 ml). Stir at 23 ° C for 16 hours.
The reaction mixture is concentrated, acetone (20 ml) is added, filtered and concentrated. 6 N HCl (30 mL) is added and heated at 80 ° C for 16 hours.
The resulting solution is cooled to 23 ° C, basified to pH 10 with KOH granules and extracted with CH2Cl2 (3x80 ml). The combined organic extracts are dried (MgSO 4), filtered and concentrated. Purify by evaporative chromatography (silica gel, eluent: 10% EtOAc-hexane). The appropriate fractions are combined and concentrated to give 1.8 g of yellow oil. EM
(FAB) m / e 218 (M + 1)
Step 2 Treat the product from step 1 (1.7 g, 8.3 mmol) in CH3OH (10 mL) with H2NOH »HCl (1.2 g, 16.8 mmol) and CH3CO2 Na (2.05 g, 25 mmol). It is refluxed for 4 hours, then cooled to 23 ° C and concentrated. Saturated NH 4 Cl is added and extracted with CH 2 Cl 2. The combined organic extracts are dried (Na 2 SO 4), filtered and concentrated to give 1.6 g of a brown oil. MS (FAB) m / e 233 (M + 1). Step 3 Treat the product of step 2 (1.5 g, 6.46 mmol) in EtOH (20 ml) with Raney nickel (1 g, wash with EtOH). Stir on a Parr shaker at 41 psi of H2 pressure for 16 hours. The reaction mixture is filtered and concentrated. Purify by evaporative chromatography (silica gel, eluent: 7% CH 3 OH with NH 3 CH 2 Cl 2). The appropriate fractions are combined and concentrated to give 0.85 g of a clear oil. MS (FAB) m / e 217 (M + 1).
Stage 4 Continue in a similar manner to that described for the preparation
306 substituting 4-amino-N-benzylpiperidine for the product from step 3. MS (FAB) m / e 211 (M + 1).
PREPARATION 5
Step 1: A solution of (f?) - (+) - 4-benzyl-2-oxazolidinone (100 g, 563 mmol) and 1.10-phenanthroline (10 mg) in dry THF (1.25 I) is cooled to -78 ° C. and / 7-BuLi is added through an addition funnel at a rate such that the internal temperature remains <; -70 ° C. Add r? -BuL¡ (350 ml of 1.6 M in hexane, 350 mmol, 1 eq.) Until the reaction turns brown from the phenanthroline complex (about 349.5 ml). After 15 minutes, 3-carbomethoxypropionyl chloride (69.5 ml, 564 mmol, 1 eq.) Is added for 10 minutes through a syringe. The resulting solution is stirred for 30 minutes at -78 ° C. The mixture is allowed to warm to 23 ° C, then it is poured into EtOAc (2.5 L) / saturated NH 4 Cl (1 L). The organic layer is washed with saturated NH 4 Cl (1 L), saturated NaHCO 3 (2.5 L) and saturated NaCl (2.5 L), and then MgSO 4 is dried and concentrated to obtain a yellow solid. The solid is recrystallized from hot isopropanol (820 ml) to give 157.9 g (542 mmol, 96%) of the pure product as a colorless crystalline solid, m.p. 90-92 ° C.
Step 2: A solution of TiCl4 (419 ml of 1M in CH2Cl2, 419 mmol) in dry CH2Cl2 (1.35 I) is cooled to 0 ° C and treated with ti (O / -Pr) 4 (41.4 ml, 140 mmol) at through a syringe. After 10 minutes at 0 ° C, diisopropylethylamine (102.4 ml, 587 mmol) is added through a dry addition funnel. The resulting solution is stirred for 15 minutes at 0 ° C and then the product from step 1 (163.2 g, 561 mmol) is added in a single portion. The solution is stirred for 1 hour at 0 ° C and then freshly distilled acrylonitrile (147 ml, 2.24 moles) is added through an addition funnel. The resulting mixture is allowed to stand at 4 ° C for 18 hours and then the reaction mixture is poured into 25% aqueous NH 4 Cl (4 L) / EtOAc (6 L). The organic layer is washed with 12.5% aqueous NH 4 Cl (2 x 41), saturated NaHC 3 (4 l), and saturated NaCl (4 l), then dried (MgSO 4) and concentrated. The crude product is dissolved in EtOAc and filtered through a pad of silica gel (500 g). The filtrate is concentrated (6 I) and crystallized from hot CH3OH (4 ml / g) to give 116.5 g (338.3 mmol, 60%) of the pure product, as a colorless crystalline solid, m.p. 103-105 ° C.
Step 3 Treat a solution of the product from step 2 (25 g, 72.6 mmol) in CHCl3 (100 ml) and CH3OH (400 ml) with PtO2 (1.25 g) and place on the Parr @ 45 psi stirrer. It is stirred for 24 hours, then the mixture is filtered through a pad of Celite. The filtrate is concentrated to give 28.3 g of crude amine »HCl.
Step 4: Treat a solution of the product of step 3 (72.6 mmol) in 1,2-dichloroethane (500 ml) with HOAc (6 ml, 105 mmol, 1.4 eq.), Followed by? / - Boc-4-piperidone. (14.6 g, 73.5 mmol, 1.01 eq.) And NaB (Oac) 3H (25.7 g, 122 mmol, 1.7 eq.). It is stirred for 1.0 hour, then the mixture is poured into CH2Cl2 (1.4 I). Wash with saturated aqueous NaHCO3 (2x560 ml), dry (MgSO4) and concentrate to give 39.1 g of the product.
Step 5 A solution of the product from step 4 (72.6 mmol) in CH3CN (500 ml) is stirred for 72 hours at 50 ° C. Cool and concentrate to give 39.3 g of lactam.
Step 6 Treat a solution of the product of step 5 (39.3 g) (containing up to 72.6 mmoles of a mixture of N-benzyl and N.methyl-cyclohexyloxazolidinones) in CH 3 OH (150 ml), with NaOH (148 ml of NaOH aqueous 1 N, 2.2 eq.) It is stirred for 6 hours at 23 ° C and then it is concentrated. H20 (50 ml) is added and washed with EtOAc (3 x 200 ml) to remove the oxazolidinone. It is acidified to pH 2 with 40 ml of 15% aqueous HCl (4.4 M) and extracted with CH2Cl2 (4 x 200 ml). The combined extracts are dried (MgSO 4) and concentrated to give the pure acid as a colorless foam (22.3 g, 65.5 mmol, 96% ee). It is recrystallized from hot acetone (18 ml / g, reflulted, filtered, cooled, approximately 300 ml of solvent is extracted in rotoevaporator, seeded and sonicated, cooled to 10 ° C, isolated by filtration with 50 ml of cold acetone washes) to give 16.5 g (48.5 mmol) of the pure product as a colorless solid, 16.5 g (48.5 mmol, 67% from the product from step 2); p.f. 145-147 ° C, > 99% ee, on a chiral HPLC column; Daicel Chiracel OD, 85:15 hexane / isopropanol with 0.1% TFA).
Step 7 Treat a solution of the product of step 6 (10.0 g, 0.029 mol) in CH2Cl2 (100 ml) with HOBT (6.0 g, 0.044 mol), the appropriate amine in THF (or dioxane) (0.044 mol), and DDC (9.1 g, 0.044 moles). Stir at 23 ° C for 4 hours. It is filtered and washed with 0.5 N NaOH, the layers are separated, extracted with CH2CI, dried (MgSO4), filtered and concentrated. Purify by evaporative chromatography (silica gel, eluent: EtOAc and then with 5% CH3OH-EtOAc). The appropriate fractions are combined and concentrated to give the product.
Step 8 Treat a solution of the product of step 7 in CH2Cl2 (125 ml) with TEA (25 ml). It is stirred at 23 ° C for 4 hours and concentrated. H20 (25 ml) is added and basified with 20% in weight of NaOH. Extract with 20% EtOH in CH2Cl2 (7x100 ml). Dry (MgSO4), filter, and concentrate to give the products 5A to 5C.
PREPARATION 6
Step 1 Use the procedures of example 11, steps 1, 2 and 3, using 3,5-dichlorobenzoyl chloride in place of 3,5-bistrifluorobenzoyl chloride, to obtain the corresponding ketone product.
Step 2 Treat the product of step 1 with H2HOH HCl using a procedure similar to that described in example 1 to obtain the title compound. Separation of the Z / E oxime mixture was carried out by chromatography with SiO 2, eluting with EtOAc: CH 2 Cl 2 mixtures to obtain the pure Z-isomer as a colorless solid.
Method A Step 3A The product from step 2 (134 g) is dissolved in CH 2 Cl 2 (1.5 I). It is treated sequentially with HOBT (44.6 g), BOC-D-phenylglycine (86.3 g) and DEC (65.9 g). The mixture is stirred at 23 ° C for 18 hours, heated at reflux temperature for 2 hours, cooled again to 23 ° C, treated with a saturated solution of NaHCO3 (500 ml), the organic portion is separated, Dry (MgSO 4), filter and concentrate. The crude material is recrystallized, once from Et2O and twice from 'Pr2O to give 1, 1-dimethylethyl- [[[1 - [[(3,5-dichlorobenzoyl) methylamine] methyl] -2- ( 3,4-dichlorophenyl) -5-methyl-hexen-1-ylidene] amino] oxy] -2-oxo-1-phenylethyl] carbamate (51 g). MS (FAB): m / e 722 [a] D23 = -96.9 ° (c 0.4 CH2Cl2); p.f. 98-102 ° C (dec).
Step 4A: The product from step 3A (25.2 g) is dissolved in a 0.5 M solution of H2NNH2 in CH2CL2: CH3OH (2: 1) (200 ml) and stirred at 23 ° C for 30 minutes. The reaction mixture is diluted with CH2CL2 (100 ml), washed with H20 (100 ml), dried (MgSO4), filtered and concentrated. The product is purified by filtration through a pad of silica gel eluting with CH2CL2 to give the title compound (15.6) g. MS (FAB): m / e 647.
Method B Step 3B The product from step 2 (750 g) is dissolved in CH 2 Cl 2 (4.5 I) at 0 ° C. It is treated sequentially with Et3N (233 g), DMAP (2.8 g) and pivaloyl chloride (204 g). The mixture is stirred at low temperature, additional CH2Cl2 (41) is added to maintain homogeneity. After 20 minutes, add H2O (100 ml), stir for 10 minutes, wash with a solution of saturated NaHCO3 (21), H2O (21), dry (Na2SO4) and concentrate at 23 ° C. The oily product is purified by filtration through a pad of silica gel eluting with CH 2 Cl 2 to obtain 3,5-dichloro-N- [3- (3,4-dichloro-phenyl) -2 - [[(2,2 -dimethyl-3-oxo-propoxy] imino] -6-methyl-5-heptenyl] -N-methylbenzamide (846 g).
Step 4B The product of step 3B was solved using a column
Chiralpak AD ™, eluting with mixtures of hexane / 'PrOH.
Step 5B The desired enantiomer of step 4B was treated according to a procedure similar to method A-step 4A to obtain the title compound.
PREPARATION 7
Step 1 Treat a solution of 3,4-dichlorophenylacetic acid (25 g) with Nt-BOC-sarcosine methyl ester (24.3 g) (prepared from HCl of sarcosine methyl ester and di-t-butyl dicarbonate) according to with a procedure similar to example 11, step 2, to obtain the desired product (36 g).
Step 2 Treat 2-bromoethanol (107 g) in CH2Cl2 (21) at 0 ° C with t-butyldimethylsilyl chloride (143 g), NET3 (130 g) and DMAP (11 g), allow the reaction mixture to warm at 23 ° C and stirred for 18 hours. The mixture is washed with H2O (250 ml), 20% HCl (250 ml), 20% NH4OH (250 ml), dried (MgSO4) and concentrated to give 2- (t-butylmethylsilyloxy) -ethyl bromide (197). ) g).
Step 3: Treat the product from step 1 (57 g) in DMF (500 ml) at -10 ° C with NaH (8.6 g, 60% disp. In oil) and stir for 1 hour. Add 2- (t-butyldimethylsilyloxy) ethylbromide (51.3 g) and Nal (6.4 g) and stir for 18 hours. EtOAc (400 mL) and a saturated NaCl solution (300 mL) are added. The organic portion is separated, dried (MgSO4), filtered and concentrated. The crude oil is purified by chromatography with silica gel eluting with EtOAc / hexane mixtures to give the product (60.1 g).
Step 4 Treat the product from step 3 (28 g) with HCl (17 g) of O-allylhydroxylamine according to a similar procedure to Example 1 to obtain the title compound (24.5 g).
EXAMPLE 1 O-Methyloxime of 1 -rr (3,5-bis (trifluoromethyl) pheninmethoxy-1,3- (3,4-dichlorophenyl) -5- (4-hiroxy-4-phenyl-1-piperidinyl) -2-pentanone
Treat a solution of the product from Preparation 1 (270 mg, 0.417 mmol) in dry pyridine (5 mL) with O-methoxylamine HCl (52 mg, 0.626 mmol, 1.5 eq) and heat at 60 ° C for 30 minutes. . The vessel is allowed to cool to 23 ° C and the pyridine is removed in vacuo. The crude product is taken up in a minimum amount of CH2Cl2 (2 ml) and applied to the silica gel column (2.5 cm x 15 cm) loaded with hexane: EtOAc: triethylamine (66: 33: 1). It is eluted with the same solvent system to obtain 190 mg (0.281 mmol, 67%) of the title compound as a colorless foam. HRMS (FAB, M + H +): m / e for [C32H33N2? 3CI2F6] +: 677.1772, found 677.1785. Example 1A (Z isomer) is prepared from the product of preparation 1 in a procedure similar to that described for example 1, using hydroxylamine HCl as starting material:
HRMS (FAB, M + H +): cale: 663.1616, found 663.1625.
EXAMPLE 2
Treat a solution of Example 1A (400 mg, 0.603 mmol) in dry DMF (12 mL) at 0 ° C with 60% NaH in mineral oil (48 mg), stir for 40 minutes and treat with methyl bromoacetate. (60 μL, 0.633 mmol, 1.05 eq). Stir for 30 minutes, pour into EtOAc (250 mL) / saturated NaHCO3 (200 mL) and extract. The organic layer is washed with water (2x100 ml), then with brine (10 ml) and dried over Na 2 SO 4. The crude mixture is purified by chromatography on silica gel (4x15 cm; hex / EtOAc 1: 1 w / 2% NEt3) to give 361.8 mg (0.492 mmol, 82%) of the pure product in the form of an oil. HRMS (FAB, M + H +): m / e cale, for [C34H34CI2F6N2? 5] +: 735.1827, found 735.1839. Using a similar procedure, treat the product of Example 1A with the appropriate alkyl halide to obtain the following compounds 2A-2C:
* Followed by distillation with 1 M TBAF in THF (3 h, 23 ° C).
EXAMPLE 3
Treat a solution of the product of Example 2 (57 mg, 0.078 mmol) in MeOH (3 mL) at 0 ° C with gaseous ammonia for 5 minutes. After airing 2-3 times, the container is closed with a polypropylene lid and stirred until the TLC shows that the reaction is complete (20 hours) to give (56 mg, 0.078 mmol,> 99%) of the product pure in the form of a colorless powder. HRMS (FAB, M + H +): m / e calculated for [C33H33CI2N3? 4] +: 720.1831, found 720.1841.
EXAMPLE 4
A suspension of H2NOH »HCl (47 mg, 0.68 mmol, 5 eq) in ethanol is treated with KOH in MeOH (680 μL, 0.68 mmol, 5 eq), sonicated for 5 minutes and then added to a solution of Example 2A (95 mg, 0.135 mmol) in ethanol (5 ml). It is heated for 2.5 hours at 60 ° C, filtered, concentrated in vacuo and purified by chromatography on silica gel (2.5 x 14 cm; CH2CL2 / MeOH (NH3) 95: 5) to give 98.3 mg (0.134 mmol, 99%) of the product in the form of a film. HRMS (FAB): 735.1956 (M + H +).
EXAMPLES 5, 5A AND 5B
Using the procedures described below, compounds of the preceding structural formula were prepared, where the definitions of R1 are shown in the following table:
EXAMPLE 5
Step 1 Prepare the allyl oxime ether of the product of Example 6, step, using O-allyl hydroxylamine HCl as alkoxy amine.
Step 2 The silyl protecting group is removed in a procedure similar to that described in example 6, step 8.
Step 3 The hydroxyl group is alkylated with 3,5-dichlorobenzyl bromide in a procedure similar to that of Example 6, step 9.
Step 4: Treat a solution of the product of step 3 (285 mg, 0.426 mmol) in 80% aqueous EtOH with Pd (PPh3) 4 (25 mg, 0.021 mmol, 0.05 eq) and triethylammonium formate (2.13 ml of solution). 1 M in THF, 5 eq) and stirred at reflux for 4 hours. Cool, concentrate and purify by chromatography on silica gel (2.5 x 16.5 cm; hex / EtOAc 1: 1 p / 2% NET3) to give 185 mg (0.3095 mmol, 73%) as a film.
Step 5 Treat the product of step 4 in a similar manner to example 2 using BrC2CN as the alkyl halide.
EXAMPLE 5A
Treat the product of example 5, step 4, similarly to example 2, using 2-bromo-1- (t-butyldimethylsiloxy) ethane as the alkyl halide followed by desilylation (3h, 23 ° C) with 1 M TBAF in THF
EXAMPLE 5B
Treat the product of example 5, step 5, similarly to example 4 to obtain the desired product.
EXAMPLE 6
Steps 1-6 3- (3,4-Dichlorophenyl) -1 - [[dimethyl (1,1-dimethyl-ethyl) silyl] oxy] -5- (4-hydroxy-4-phenol-1- piperidinyl) -2-pentanone as described in U.S. Patent 5,696,267.
Step 7 Treat a solution of the product of step 6 (6.6 g, 12.3 mmol) and NaOAc (6.05 g, 73.8 mmol) in EtOH (100 mL) and H20 (27 mL) with NH2OCH3 »HCl. The resulting solution is stirred for 12-18 hours at room temperature. Concentrate under reduced pressure and partition the resulting residue between CH2Cl2 (100 mL) and H20 (100 mL). The aqueous layer is extracted with CH2Cl2 (3x100 ml), the combined organic layers are dried over MgSO4, filtered and concentrated under reduced pressure to obtain the crude product as a pale oil. This product is passed without purification to the next stage. HRMS (FAB, M + H +): m / e calculated for [C29H43N203SiCl2] +: 565.2420, found 565.2410.
Step 8 Treat a crude oxime solution from step 7 (< 12.3 mmol) in THF (400 mL) with TBAF (15.4 mL, 15.4 mmol, 1 M in THF) at 0 ° C. The solution is stirred for 2 hours. The reaction is quenched with water and the aqueous phase is extracted with EtOAc (3x100 ml). The combined organic layers are dried over MgSO 4, filtered and concentrated under reduced pressure to give the crude product as a yellow oil. Purify by silica gel chromatography (column: 7.5 cm x 20 cm), load the column into CH2Cl2 and elute using a gradient of 100% CH2Cl2 at 5% CH3OH (NH3) / CH2Cl2 to obtain 16 g (29.9 mmol, 75% from step 6) of the desired compound as a white solid HRMS (FAB, M + H +): m / e calculated for [C 23 H 29 N 2 O 3 Cl 2] +: 451.1555, found 451.1553.
Step 9 Treat a solution of the product of step 8 (200 mg, 0.44 mmol) in DMF at 0 ° C with NaH (12 mg, 0.48 mmol). The resulting mixture is stirred for 30 minutes at 0 ° C. 2,4-Difluorobenzyl bromide (60 μL, 0.465 mmol) is added in a single portion and the cooling bath is removed. The reaction is stirred for 12-18 hours at room temperature. The reaction is quenched with H2O and extracted with EtOAc (3x30 mL). The combined organic layers are dried over MgSO, filtered and concentrated under reduced pressure to give the crude compound as a yellow oil. Purify by silica gel chromatography (column: 2.5 cm x 15 cm, load the column in 50% EtOAc / Hexane and elute using a gradient of 50-100% EtOAc / Hexane) to obtain 128 mg (0.22). mmoles, 50%) of the title compound in the form of a pale-colored oil. HRMS (FAB, M + H +): m / e calculated for [C30H33N2O3CI2F2] +: 557.1836, found 577.1832.
-EJEMPLO 7
Step 1 The product from example 6, step 8 (1.8 g) and TFA (0.31 μL) is added to the acid or yodoxibenzoic (2.24 g) in DMSO (20 ml). The mixture is stirred for 2 hours and ice / H 2 O (50 ml), concentrated NH 4 OH solution (5 ml) and EtOAc (50 ml) are added. The mixture is stirred and filtered to remove the solids. The solid residue is washed with H20 (2 × 20 ml) and EtOAc (2 × 20 ml). The filtrates are combined, the organic layer is separated and washed with H20 (2x25 ml), dried over MgSO4, filtered and evaporated to give 3- (3,4-dichlorophenyl) -5- (4-hydroxy-4). phenyl-1-piperidinyl) -2- (2-methoxyimino) pentanal (1.8 g) in the form of a foamy solid. Mass spectrum (FAB): 449
Step 2 Treat the product from step 1 (0.2 g) in CF3CH2OH (5 ml) with 3Á molecular sieves (1.0 g) and 3,5-bistrifluoromethylbenzylamine (0.14 g).
The mixture is stirred for 90 minutes and NaBHsCN (0.12 g) is added. After 18 hours the reaction mixture is filtered through a pad of Celite, rinse the pad of Celite with MeOH (10 ml) and evaporate the combined filtrates. The residue is partitioned between CH2Cl2 (15 mL) and 20% KOH (15 mL). The organic layer is separated and the aqueous layer is extracted with CH2Cl2 (2 × 20 ml). The organic extracts are combined, dried over MgSO4, filtered and evaporated to give a solid. Purify the crude product by chromatography with silica gel eluting with NH3 / MeOH / CH2Cl2 mixtures to obtain the title compound (0.1 g) HRMS (FAB, M + H +): m / e calculated for [C32H34N3O6CI2F6] +: 676.1932 , found 676.1940.
EXAMPLE 7A 3- (3,4-Dichlorophenyl) -5- (4-hydroxy-4-phenyl-1-piperidinyl) -1 -IT2-methoxyphenyl) methylaminol-2-pentanone O-methyloxime.
Using the product of example 7, step 1 as a starting material, the compound of example 7A is prepared using 2-methoxybenzylamine in a procedure similar to that described in example 7, step 2. HRMS (FAB, M + H +): m / e calculated for [C31H37N3? 3CI2] +: 570.2290, found 570.2291
EXAMPLE 8
Treat the product of example 7A (50 mg) in CH2Cl2 (5 ml) with
HOBT (12.4 mg) and AcOH (1 ml) and cooled to 0 ° C. To the cold solution is added DEC (17.6 mg) and stirred for a further 18 hours. The reaction mixture is washed with a 10% solution of NH 4 OH (3 ml). The aqueous layer is extracted again with CH2Cl2 (3x3 ml), the organic portions are combined, dried over MgSO4, filtered and evaporated to give a solid. Purify the crude product by chromatography with silica gel eluting with mixtures of NH3 / MeOH / CH2CI2 to give the title compound (0.042 g). Analysis: Calculated for C33H39N304CI2. 0.5H2O; C, 63.76, H,
6. 49, N, 6.76. Found: C, 63.83, H, 6.85, N, 6.95.
EXAMPLE 9
Step 1-7 O - Methyloxime of 1 - [[3,5-bis (trifluoromethyl) phenyl] methoxy] -3- (3,4-dichlorophenyl) -5-hydroxy-2-pentanone is prepared as described in U.S. Patent 5,696,267.
Step 8 Oxalyl chloride (2.01 g, 15.82 mmol) is dissolved in dry CH2Cl2 (30 mL) and cooled to -78 ° C under N2, DMSO (2.47 g, 31.64 mmol) in dry CH2Cl2 (12 mL) is added per drip and stir at -78 ° C for 15 minutes. The product of step 7 (6.56 g, 12.66 mmol) in dry CH 2 Cl 2 (20 ml) is added dropwise and stirred at -78 ° C for 3 hours. Diisopropylethylamine (4.91 g, 37.97 mmol) is added and stirred at -78 ° C for 1 hour. Heat slowly to 0 ° C and stir at 0 ° C for 30 minutes. Water (150 ml) is added and extracted with CH2Cl2. The combined extracts are washed with saturated aqueous NaCl, dried (MgSO4), filtered, and concentrated to give 6.53 g (12.66 mmol, 100%) of a yellow oil. MS (FAB): m / e 516 (M + 1) -
Step 9 Dissolve the product (1.05 g, 2.03 mmol) of step 8 and 4-phenylamino-piperidine (1.08 g, 6.13 mmol) in CF3CH20H (10 mL), add crushed 3A sieves (1 g) and NaBH3CN (0.26). g, 4.07 mmol), and stirred at 23 ° C for 4 hours. Concentrate and add water (60 ml) and EtOAc (60 ml). Filter through Celite, separate the filtrate layers and extract the aqueous solution with EtOAc. The combined organic extracts are dried (MgSO 4), filtered and concentrated. Purify by chromatography (200 ml of evaporative silica gel, eluent: 3% CH3OH-CH2Cl2). The appropriate fractions are combined and concentrated to give 0.98 g (1.45 mmol, 66%) of the title compound as a yellow oil. MS (FAB): m / e 676 (M + 1). The following compound of formula 9A is prepared by reaction of the product of example 9, step 8, with an appropriate amine according to the procedure of the example, step 9:
MS (FAB): m / e 657 (M + 1)
EXAMPLE 10
Dissolve the product (0.380 g, 0.578 mmol) of Example 9A in THF (3 mL) and CH3OH (1 mL). Add 1 N KOH (2.7 mL, 2.70 mmol) and reflux for 16 hours. It is cooled to 23 ° C and 1 N HCl (5 ml) and water (20 ml) are added. Extract with CH2Cl2 (3x20 mL), wash the combined organic extracts with saturated aqueous NaCl, dry (MgSO4), filter and concentrate to give 0.312 g (0.496 mmol, 86%) of the title compound as a foam yellow. MS (FAB): m / e 629 (M + 1)
EXAMPLE 11
A suspension of sarcosine methyl ester hydrochloride (6.02 g, 43 mmol) in CH2CL2 (250 ml) is treated at 0 ° C with 3 5-bistrifluoromethyl benzoyl chloride (7.7 ml, 42.5 mmol) and Et3N (12.5 ml). , 89.7 mmoles). The mixture is stirred at 20 ° C for 1 hour. Water (150 ml) is added to the mixture and the organic layer is separated. Dry (MgSO4) and concentrate the organic layer to give the crude product. Purify by chromatography with silica gel (eluent: EtOAc: hexane (6: 4)) to obtain 12 g of the product (81%).
Stage 2:
Treat a solution of 3,4-dichlorophenyl acetic acid (4.15 g, 20 mmol) in anhydrous THF (50 mL) at -60 ° C with [(CH 3) 3 Si] 2 NLi (46.2 mL, 46.2 mmol) and heat slowly. Mix at 0 ° C for 4 hours. This solution is transferred to a solution of the product from step 1 (5.46 g, 16 mmol) in anhydrous THF (8 ml) at -30 ° C. The reaction is heated at -10 ° C for 1 hour, stirred at 0 ° C for 1 hour and at 20 ° C for 4 hours. 50% aqueous HOAc (15 mL) is added and extracted with EtOAc. The organic layer is separated, dried (MgSO4) and concentrated to give the crude product. Purify by chromatography with silica gel (eluent: hexane / EtOAc, 6: 4) to give 5.21 g (69%) of the product. HRMS (FAB, M + H) = m / e calculated for [C19H14NO2CI2F6] + = 472.0306, found 472.0306.
Treat a solution of the product from step 2 (0.96 g, 2 mmol) in THF (6 ml) at -78 ° C with [(CH 3) 3 Si] 2 N Li (2.5 ml, 2.5 mmol) and stir at -78 °. C for 25 hours. A solution of 1-bromo-3-methyl-2-butene (0.42 g) in THF (1 ml) is added to the above anionic solution at -78 ° C, the solution is slowly heated to 0 ° C and stirred at 20 ° C for 2 hours. A saturated solution of NH 4 Cl (5 mL) is added, extracted with EtOAc twice and the combined EtOAc extracts are washed with brine, dried (MgSO 4) and concentrated to give a crude product. Purify by column chromatography (silica gel, eluent: EtOAc: hexane, 2: 8) to obtain 1 g of product (87%). MS (FAB, M + H +) m / e 540.
Treat a solution of the product from step 2 (0.22 g, 0.4 mmol) in pyridine (3 ml) at 70 ° C with methoxylamine HCl (95 mg, 1.14 mmol), stir at 70 ° C for 6.5 hours and then it is cooled to 20 ° C. Water is added to the reaction mixture, the solution is extracted with EtOAc, dried (MgSO4) and the EtOAc extracts are concentrated to give the crude product. Purify by chromatography with silica gel (eluent: hexane: Et20, 1: 1) to give 74 mg (32%) of the Z isomer and 130 mg (56%) of the E-isomeric oximes. MS (FAB, M + H +) = m / e 569.
Stage 5A
Treat the product of step 3 (0.387 of E-isomer, 0.68 mmole) in a saturated EtOAc solution at 03 to -78 ° C for 5 minutes. The solution is purged with N2) (CH3) 2S is added and the solution is heated from -78 ° C to 20 ° C for 1 hour. The solution is concentrated to give the desired aldehyde which is used directly in the next reaction without further purification. MS (FAB M + H +) = m / e 543.
Stage 5B
The Z-isomer is prepared using a procedure similar to that described in step 5A employing the Z-isomer product of step 4.
Step 6 Treat the product of step 5 with 4-hydroxy-4-phenylpiperidine in a procedure similar to that described in example 9, step 9, to obtain the title compound (Z-isomer) with a general yield of 77%. %. HRMS (FAB, M + H +) = m / e calculated for [C33H34N3? 3CI2F6] +: 704.1881, found 704.1875.
EXAMPLE 12
Step 1 Using the procedures of Example 11, using 3,5-dichlorobenzoyl chloride in place of 3,5-bistrifluorobenzoyl chloride in step 1, proceed through steps 2, 3, 4 and 5, to obtain the composed of the title. Alternatively, to prepare an optically active material, the product of preparation 6 is treated according to the procedure indicated in example 13, step 1.
Step 2 The following compounds of formula 12A to 12S are prepared by reaction of the product of step 1 with an appropriate amine (described in preparations 3 and 4) according to a similar procedure to example 9, step 9. The stereoisomers are separated HPLC on a chiral column using mixtures of hexane and isopropanol with 0.25% Et2NH adding to a Daicel AD and / or OD column.
EXAMPLE 13
Step 1 Treat the product of preparation 6 with CH3I using the procedure of Example 2, followed by a procedure similar to Example 11, step 5, to obtain the title compound.
Step 2 The following compounds are prepared by reaction of the product from step 1 with an appropriate amine (for 13A to 13C see preparation 5A-5C, for 13D see preparation 3O6, for 13F to treat the product of preparation 5, step 5, using a procedure similar to that described in preparation 2, step 4, to obtain the appropriate amino ester) according to a procedure similar to that of example 9, step 9, substituting NaBH3CN for NaB (OAc) 3H and trif I uore tanol for 1, 2-dichloroethane. 13 G are prepared by treatment of Example 13D with MCPBA in CH CI2 at 0 ° C for 3 hours; similarly prepared 13H by treatment of 13B. Example 13E is prepared from example 13F using conventional saponification conditions similar to those described in preparation 5, step 6.
EXAMPLE 14
EXAMPLE 14A
Treat the product of Preparation 7 according to a procedure similar to that described in Example 6, Step 8. Continue in a manner similar to that described in Example 9, Steps 8-9, using the product of Preparation 5A or 3A6 in the place of 4-phenylamino-piperidine. The procedure is similar to that of preparation 2, step 4, optionally replacing TFA with HCl. The amine is acylated according to a procedure similar to preparation 2, step 2A using 3,5-dichlorobenzoyl chloride.
EXAMPLE 14B
Treat the product of example 14A using a procedure similar to example 5, step 4, to obtain the oxime. Alternatively, for the preparation of the optically active material, the product of preparation 6 is treated according to a procedure such as that indicated in example 11, step 5B, followed by the procedure of example 13A, step 2.
EXAMPLE 14C
Treat the product of Example 14B with BrCH2CN according to a procedure similar to Example 2A to give the title compound.
EXAMPLE 14D
A procedure similar to that described in Example 4 is used using the product of Example 14C to obtain the title compound. The stereoisomers are separated by HPLC on a chiral column using mixtures of hexane and isopropanol with 0.25% Et2NH added on a Daicel AD and / or OD column.
EXAMPLE 14E
Treat the product of Example 14C according to a procedure similar to that of Example 18M to obtain the title compound.
EXAMPLE 15
EXAMPLE 15A
Step 1 Treat the product of preparation 7 using a procedure similar to that described in example 6, step 8. Continue in a manner similar to that described in example 9, steps 8-9, using the product of preparation 5B or 3B6 instead of 4-phenylamino-piperidine. The process is continued in a manner similar to the procedure indicated in Preparation 2, step 4, optionally substituting TFA for HCl. The amine is acylated according to the procedure similar to preparation 2, step 2A, using 3,5-dichlorobenzoyl chloride.
Step 2: Treat the resulting product using a procedure similar to Example 5, step 4, to obtain the title compound.
Alternatively, for the preparation of the optically active material, the product of preparation 6 is treated according to a procedure such as that indicated in example 11, step 5, followed by the procedure of example 13B, step 2.
EXAMPLE 15B
The product of step 2 is treated with BrCH2CN according to a procedure similar to example 2A to obtain the title compound.
EXAMPLE 15C
The product of Example 15A is alkylated and deprotected according to a procedure similar to Example 2B to give the title compound.
EXAMPLE 15D
Step 1 The product is alkylated in Example 15A with allyl chloroacetate according to a similar procedure to Example 2 to obtain the resulting allyl ester.
Step 2: Treat a solution of the product from step 1 according to a procedure similar to that of example 3 to give the title compound.
EXAMPLE 15E
Treat a solution of Example 15D, Step 1, with CH3NH2 according to a procedure similar to that of Example 3 to give the title compound.
EXAMPLE 15F
A procedure similar to that described in Example 4 is used using the product of Example 15B to obtain the title compound. The stereoisomers are separated by HPLC on a chiral column using mixtures of hexane and urea propanol with 0.25% diethylamine added on a Daicel AD and / or OD column.
EXAMPLE 15G
Step 1 The product of example 15D, step 1, is deprotected using a procedure similar to that of example 5, step 4.
Step 2: Treat a solution of the product from step 1 (82 mg) in dry CH 2 Cl 2 (1 ml) with NEt 3 (41 μl). followed by BOP-CI (36.5 mg). Stir 15 minutes at 23 ° C, then add 2-amino-1, 3,4-thiadiazole (14 mg). Stir for 2 hours, dilute with EtOAc (75 mL) and wash with 10% citric acid followed by H2O, and then with saturated NaHCO3. The organic layers are dried (Na2SO4), filtered, concentrated and purified by chromatography with silica gel to give the title compound.
EXAMPLE 15H
The product of Example 15A is rented using a procedure similar to that described in Example 2 using 1,3-propane sulfone in place of methyl bromoacetate to obtain the title compound.
EXAMPLE 151
The product of example 15G, step 1, is coupled with H2NCH2CN using a procedure similar to that of example 8 to obtain the title compound.
EXAMPLE 15J
The product of example 15G, step 1 is coupled with H2NCH2SO3H using the procedure similar to that of example 8 to obtain the title compound.
EXAMPLE 15K
The product of Example 15A is rented using a procedure similar to that described in Example 2 using BrCH2F in place of methyl bromoacetate to obtain the title compound.
EXAMPLE 15L
The product of Example 15A is treated with iodoethane according to a procedure similar to that of Example 2, to obtain the title compound.
EXAMPLE 15M
Treat the product of Example 15B according to a procedure similar to that of Example 18M to obtain the title compound.
EXAMPLE 16
EXAMPLE 16A
Step 1 Treat the product of preparation 7 using a procedure similar to that described in example 6, step 8. Continue in a manner similar to that described in example 9, steps 8-9, using the product of preparation 5C or 3C6 instead of 4-phenylamino-piperidine. The process is followed in a manner similar to the procedure indicated in Preparation 2, step 4, optionally substituting TFA for HCl. The amine is acylated according to a procedure similar to preparation 2, step 2A, using 3,5-dichlorobenzoyl chloride.
Step 2: Treat the resulting product using a procedure similar to Example 5, step 4, to obtain the title compound. Alternatively, for the preparation of the optically active material, the product of preparation 6 is treated according to a procedure indicated in example 11, step 5, followed by the procedure of example 13C, step 2.
EXAMPLE 16B
The product of step 2 is treated with BrCH2CN according to a procedure similar to that of example 2A to obtain the title compound.
EXAMPLE 16C
The product of Example 16A is alkylated and deprotected according to a procedure similar to that of Example 2B to obtain the title compound.
EXAMPLE 16D
Step 1 The product of Example 16A is alkylated with allyl chloroacetate according to a similar procedure to Example 2 to obtain the resulting allyl ester.
Step 2: Treat a solution of the product from step 2 according to a procedure similar to that of example 3, to obtain the title compound.
EXAMPLE 16E
Treat a solution of example 16D, step 1, with CH3NH2 according to a procedure similar to that of example 3 to obtain the title compound.
EXAMPLE 16F
A procedure similar to that described in Example 4 is used using the product of Example 16B to obtain the title compound. The stereoisomers are separated by HPLC on a chiral column using mixtures of hexane and isopropanol with 0.25% Et2N added on a Daicel AD and / or OD column.
EXAMPLE 16G
Step 1 The product of example 16D, step 1, is deprotected using a procedure similar to that of example 5, step 4.
Step 2: Treat the product of step 1 according to a procedure similar to that of example 15G, step 2, to give the title compound.
EXAMPLE 16H
The product of Example 16A is alkylated using a procedure similar to that described in Example 2, using 1,3-propane sulfone in place of methyl bromoacetate to obtain the title compound.
EXAMPLE 161
The product of example 16G, step 1, is coupled with H2NCH2CN using a procedure similar to that of example 8, to obtain the title compound.
EXAMPLE 16J
The product of example 16G, step 1, is coupled with H2NCH2SO3H using a procedure similar to that of example 8 to give the title compound.
EXAMPLE 16K
The product of Example 16A is rented using a procedure similar to that described in. Example 2 employing BrCH F in place of methyl bromoacetate to obtain the title compound.
EXAMPLE 16L
Treat the product of example 16A, step 2 with CH3CH2I according to a procedure similar to example 2 to obtain the title compound.
EXAMPLE 16M
Treat the product of Example 16B according to a procedure similar to Example 18M to obtain the title compound.
EXAMPLE 17
EXAMPLE 17A
Step 1 Treat the product of preparation 7 using a procedure similar to that described in example 6, step 8. The procedure is similar to that described in example 9, steps 8-9, using the product of preparation 306 in 4-phenylamino-piperidine. The process is followed in a manner similar to the procedure indicated in Preparation 2, step 4, by optionally substituting TFA for HCl. The amine is acylated according to a procedure similar to preparation 2, step 2A, using 3,5-dichlorobenzoyl chloride.
Step 2: Treat the resulting product using a procedure similar to Example 5, step 4, to obtain the title compound. Alternatively, for the preparation of the optically active material, the product of preparation 6 is treated according to a procedure indicated in example 11, step 5, followed by the procedure of example 13D, step 2.
EXAMPLE 17B
Example 17A is rented with CH3I according to a similar procedure to Example 2 to give the title compound.
EXAMPLE 17C
The product of Example 17A is alkylated and deprotected according to a procedure similar to Example 2B to give the title compound.
EXAMPLE 17D
Example 17A is alkylated with BrCH2CN according to a similar procedure to Example 2A to give the title compound.
EXAMPLE 17E
A procedure similar to that described in Example 4 is used, using the product of 17D to obtain the title compound.
EXAMPLE 17F
Step 1: Example 17A is alkylated with allyl chloroacetate according to a similar procedure to Example 2 to give the resulting allyl ester.
Step 2: Treat a solution of the product from step 1 according to a procedure similar to that of example 3 to give the title compound.
EXAMPLE 17G
Treat a solution of example 17F, step 1 with (CH3) 2NH according to a procedure similar to that of example 3 to obtain the title compound.
EXAMPLE 17H
Treat a solution of example 17F, step 1 with CH3NH2 according to a procedure similar to that of example 3 to obtain the title compound.
EXAMPLE 171
Step 1 The product from example 17F, step 1, is deprotected using a procedure similar to that of Example 5, step 4.
Step 2 Treat the product of step 1 according to a procedure similar to example 15G, step 2 to give the title compound.
EXAMPLE 17J
Example 17A is rented with 3-bromo-1-t-butyldimethylsilyloxypropane and deprotected using a procedure similar to that described in Example 2B to obtain the title compound.
EXAMPLE 17K
Example 17A is rented using a procedure similar to that described in Example 2, employing 1,3-propane sulfone in place of methyl bromoacetate to obtain the title compound.
EXAMPLE 17L
Step 1 The product of Example 17A is alkylated with methyl bromoacetate using a procedure similar to that described in Example 2 to obtain the methyl ester.
Step 2: Treat the product of step 1 according to a procedure similar to that of example 4 to obtain the title compound.
EXAMPLE 17M
Step 1 The product of example 17A is alkylated with bromopropylphthalimide using a procedure similar to that described in example 2C to obtain the protected propylamine.
Step 2: Treat the product from step 1 with (CH3) NH2 according to a procedure similar to that of example 3 to obtain the primary amine.
Step 3 Treat the product from step 2 (150 mg) in CH2Cl2 (3 ml) with methyl isocyanate (14.7 mg) and stir for 1 hour. The solvent is evaporated and purified by chromatography with silica gel using CH 2 Cl 2 / CH 3 OH saturated with ammonia to provide 137 mg (86%) of the title compound.
EXAMPLE 17N
Step 1: A solution of example 17J (1.0 g) in CH2Cl2 (20 ml) is cooled and then treated with Net3 (507 μl). The solution is heated to 0 ° C and stirred for 30 minutes. Pour into EtOAc / NaHCO3. The organic layer is washed with H2O, brine and dried (Na2SO4). The solvent is removed to provide the mesylate (quantitative).
Step 2 Treat a solution of the product from step 1 in dry DMF with NaSCH3. The solution is stirred for 45 minutes, and then the mixture is poured into EtOAc / aqueous NaHCO 3. The organic layer is washed with H20 and with brine, and dried (Na2SO4) and purified by chromatography with silica gel using EtOAc / Net3 to obtain 282 mg (86%) of the methyl sulfide.
Step 3: The product of step 2 (64 mg) is dissolved in THF (2 ml) and treated with t-butanol (500 μl), osmium tetroxide (56 μl of a 2.5% solution in t-butanol) and NMO (31.6 mg) and the mixture is stirred for 2 hours at 23 ° C. The mixture is poured into EtOAc / aqueous NaHSO4. The organic layer is washed with saturated aqueous NaHC03 and with brine, dried (Na2SO4), filtered, and concentrated and purified by chromatography with silica gel using EtOAc / Ne.3 to provide 57 mg (85%) of the title compound. Title.
EXAMPLE 170
The product from Example 17A is alkylated and deprotected according to a procedure similar to Example 17J by substituting 3-bromo-1-t-butyldimethylsilyloxy propane for 2-bromo-1-t-butyldimethylsilyloxy ethane. The product is converted to methyl sulfone according to a procedure similar to that described in example 17N.
EXAMPLE 17P
The product of example 17N step 2 (128 mg) is dissolved in
CH2CI2 (5 ml) and treated with ReOCI3 (PPh3) 4 (7.5 mg) and phenyl sulfoxide (51 mg). Stir for 3 hours at 23 ° C, and then add ReOCI3 (PPh3) 4 (7.5 mg) and phenyl sulfoxide (51 mg) and stir at 23 ° C for 15 hours. H 0 (20 ml) was added and extracted with CH 2 Cl 2. Dry the organic layer with MgSO 4 and concentrate. Purify using chromatography with silica gel (EtOAc / Net3 / CH3OH as eluent) to obtain 95 mg (72%) of the title compound.
EXAMPLE 17Q
The product of example 17A is alkylated with the product of example 18L, step 2, using a procedure similar to that described in example 18L, step 3, to obtain the title compound.
EXAMPLE 17R
Treat the product of example 17L with an excess of diazomethane in Et20 to obtain the title compound.
EXAMPLE 17S
The product from Example 17A is rented using a procedure similar to that described in Example 2 using BrCH2F in place of methyl bromoacetate to obtain the title compound.
EXAMPLE 17T
Treat the product of Example 17D according to the procedure similar to that of Example 18M to obtain the title compound.
EXAMPLE 18
EXAMPLE 18 A
Step 1: Treat the product of Preparation 7 using a procedure similar to that described in Example 6, Step 8. Continue in a manner similar to that described in Example 9, Steps 8-9, using the product of Preparation 306 in Instead of 4-phenyl-piperidine. The process is followed in a manner similar to the procedure indicated in Preparation 2, step 4, by optionally substituting TFA for HCl. The amine is acylated according to a similar procedure in preparation 2, step 2A, using 3,5-dimethylbenzoyl chloride.
Step 2: Treat the resulting product using a procedure similar to Example 5, step 4, to obtain the title compound. Alternatively, for the preparation of the optically active material, the product derived from a procedure similar to that of preparation 6, steps 1 and 2, is treated, replacing the 3,5-dichlorobenzoyl chloride in stage 1 with 3,5-dimethylbenzoyl chloride , and solving the product of step 2 in a procedure similar to that described in preparation 6, step 4B. The procedure indicated in example 11, step 5 is continued, followed by the procedure of example 13D, step 2.
EXAMPLE 18B
Example 18A is rented with CH3I according to a procedure similar to that of Example 2 to give the title compound.
EXAMPLE 18C
The product from Example 18A is rented and deprotected using a procedure similar to Example 2B to give the title compound.
EXAMPLE 18D
Example 18A is rented with BrCH2CN according to a procedure similar to example 2A to give the title compound.
EXAMPLE 18E
A procedure similar to that described in example 4 is used, using the product 18D to obtain the title compound.
EXAMPLE 18F
Step 1: Example 18A was alkylated with allyl chloroacetate according to a similar procedure to Example 2 to obtain the allyl ester.
Step 2 The product of step 1 is deprotected using a procedure similar to that of example 5, step 4.
Step 3 The product of step 2 is coupled with 2-amino-1,4-thiadiazole using a procedure similar to example 15G, step 2 to give the title compound.
EXAMPLE 18G
Example 18A is rented with 3-bromo-1-t-butyldimethyl-silyloxypropane and deprotected using a procedure similar to that described in Example 2B to obtain the title compound.
EXAMPLE 18H
Treat the product of example 18F, step 1, with morpholine at 65 ° C using a procedure similar to that of example 3 to give the title compound.
EXAMPLE 181
Treat the product of example 18F, step 1 at 23 ° C with n-methylpiperazine using a procedure similar to that of example 3 to obtain the title compound.
EXAMPLE 18J
The product of Example 18F, Step 2, is coupled with thiomorpholine using a procedure similar to that of Example 8 to give the title compound.
EXAMPLE 18K
The product from example 18F, step 2, is coupled with 2-aminothiazole using a procedure similar to that of example 18F, step 3, to obtain the title compound.
EXAMPLE 18L
Step 1 Treat a solution of CH3ONH2 »HCl (2.5 g) in H20 (40 ml) with NaHCO3 (5 g). It is cooled to 0 ° and a solution of CICH2COCI (2.4 ml) in THF (20 ml) is added at a rate sufficient to maintain the internal temperature at 0-3 ° C. Upon completion of the addition, it is heated to 23 ° C and stirred for 2 hours. The pH is adjusted to 5 (Na 2 CO 3), the THF is removed in vacuo, and NaCl is added and extracted with CH 2 Cl 2. Dry the organic layer (Na2SO4), filter and concentrate to give the a-chloroamide.
Step 2: Treat a solution of the product of step 1 (131 mg) in acetone (1 ml) with Nal (158 mg). It is stirred for 7 hours at 23 ° C, the solvent is removed in vacuo, redissolved in THF, filtered through Celite and concentrated to give the iodoamide.
Step 3: Example 18A was alkylated with the product of example 18L, step 2, using a procedure similar to that described in example 2 using 2.5 equivalents of NaH to obtain the title compound.
EXAMPLE 18M
A procedure similar to that described in Example 4 is used using the 18D product and the following modifications: HONH2"HCl is replaced by CH3ONH2» HCl, and 2,2,2-trifluoroethanol is used as the solvent, and is stirred at 70 °. C for a week to obtain the title compound.
EXAMPLE 18N
The product of 18C is treated according to a procedure similar to that of example 17M, step 3.
EXAMPLE 19
EXAMPLE 19A
Step 1 Treat the product of preparation 7 using a procedure similar to that described in example 6, step 8. Continue in a manner similar to example 9, step 8-9, using the product of preparation 5A or 3A6 instead of 4-phenylamino-piperidine. The procedure is similar to the procedure described in Preparation 2, step 4, optionally replacing TFA with HCl. The amine is acylated according to a procedure similar to preparation 2, step 2A, using 3,5, -dimethylbenzoyl chloride.
Step 2 Treat the product of step 1 using a procedure similar to that of example 5, step 4 to obtain the title compound. Alternatively, for the preparation of the optically active material, the product derived from a procedure similar to that of preparation 6, steps 1 and 2, is treated, replacing the 3,5-dichlorobenzoyl chloride of step 1 with 3,5-dimethylbenzoyl chloride , and solving the product of step 2 in a procedure similar to that described in preparation 6, step 4B. Continue with the procedure indicated in the example, 11, step 5, followed by the procedure of example 13A, step 2.
EXAMPLE 19B
The product of Example 19A was alkylated with BrCH2CN using a procedure similar to that of Example 2A to give the title compound.
EXAMPLE 19C
A procedure similar to that described in Example 4 is used using the product of Example 19B to obtain the title compound.
EXAMPLE 19D
Step 1 The product of example 19A is alkylated with allyl chloroaceate according to a procedure similar to example 2 to give allyl ester.
Step 2 Treat the product of step 1 using a procedure similar to that of example 5, step 4.
Step 3 The product from step 2 is coupled with 2-amino-1,4-thiadiazole according to a procedure similar to example 15G, step 2 to give the title compound.
EXAMPLE 19E
The product of example 19A is alkylated with the product of example 18L, step 2, using a procedure similar to that described in example 2 using 2.5 equivalents of NaH to obtain the title compound.
EXAMPLE 20
EXAMPLE 20A
Step 1: Treat the product of preparation 7 using a procedure similar to that described in example 6, step 8. Continue in a manner similar to example 9, steps 8-9 using 4-hydroxy-4-phenylpiperidine in Place of 4-phenylamino-piperidine. Continue in a manner similar to the procedure of Preparation 2, step 4, optionally substituting TFA for HCl. The amine is acylated according to a procedure similar to preparation 2, step 2A, using 3,5-dimethyoxybenzolyl chloride.
Step 2 Treat the product of step 1 using a procedure similar to that of example 5, step 4.
Step 3 The product of step 2 is alkylated with BrCH2CN according to a procedure similar to that of example 2A to obtain the title compound.
Step 4 A procedure similar to that described in Example 4 is used using the product from step 3 to obtain the title compound.
EXAMPLE 20B
The product of example 20A, step 2 is alkylated with 2-bromo-1 t-butyldimethylsilyloxy ethane and deprotected using a procedure similar to that of example 2B to obtain the title compound.
EXAMPLE 21
EXAMPLE 21A
Step 1: Treat the product of preparation 7 using a procedure similar to that described in example 6, step 8. Continue in a manner similar to that described in example 9, steps 8-9, using the product of preparation 306 in place of 4-phenylamino-piperidine. The process is followed in a manner similar to the procedure indicated in Preparation 2, step 4, by optionally substituting TFA for HCl. The amine is acylated according to a procedure similar to preparation 2, step 2A, using 4-methyl-3,5-dimethoxybenzoyl chloride.
Step 2 Treat the product of step 1 using a procedure similar to example 5, step 4.
Step 3: Rent the product from step 2 with BrCH2CN using a procedure similar to example 2A to give the title compound.
EXAMPLE 21 B
Treat the product of Example 21 A using a procedure similar to that described in Example 4 to obtain the title compound.
EXAMPLE 22
A procedure similar to that described in Example 20A was used using the product of preparation 306 instead of 4-h.drox.-4-phenylpiperidine in step 1 to obtain the title compound. HRMS (FAB, M + H +): m / e cale. To: 691.2778, found 691.2769.
EXAMPLE 23
A procedure similar to that described in Example 20A was used using 3,4,5-trimethoxybenzoyl chloride as the acid chloride in step 1 to obtain the title compound; MS (FAB): m / e 716 (M + 1).
EXAMPLE 24
A procedure similar to that described in Example 11 was used using the product of preparation 306 as an amine in step 6 to obtain the title compound HRMS (FAB, M + H +): m / e cale, for: 709.2147 found 709.2138.
EXAMPLE 25
Using a procedure similar to that of Example 2, the product of example 3H5 was methyl, replacing methyl iodide with methyl bromoacetate. The resulting product was deprotected and coupled to the product of example 12, step 1 using the procedure of example 9, step 9, to obtain the title compound. HRMS (FAB, M + H +): m / e cale, for: 798.2537; finding 798.2538.
EXAMPLE 26
A procedure similar to that described in Example 17B was used using 3-chloro-5-methyl-benzoyl chloride in place of 3,5-dichlorobenzoyl chloride (step 1, example 17A) to obtain the title compound. HRMS (FAB, M + H +): m / e cale, for: 621.2166; Found 621.2178.
EXAMPLE 27
A procedure similar to that described in Example 13A was used employing 3-chloro-5-methyl-benzoyl chloride in place of 3,5-dichlorobenzoyl chloride to obtain the title compound. HRMS (FAB, M + H +): m / e cale, for: 706.2694, found 706.2701.
EXAMPLE 28
Step 1: Glycine was condensed with 3,5-dichlorohezoic acid according to a similar procedure to Example 8. The resulting amide was treated with NaH followed by iodoethane according to Example 2. The resulting material was treated with diazomethane to give methyl ester of N-ethyl-N- (3,5-dichlorobenzoyl) -glycine.
Step 2 The procedures of example 11, steps 2-5 were used, substituting the product of step 1 for the product of example 11, step 1. An optically active material can be prepared using procedures similar to those of preparation 6. The compounds The following were prepared by reacting the product of step 2 with an appropriate amine (for 28A to 28C, see preparation 5A-5C; for 28D, see preparation 306) according to a procedure similar to example 9, step 9, substituting NaB3HCN for NaB (OAc) 3H and optionally substituting 2,2,2-trifluoroethanol for 1,2-dichloroethane.
EXAMPLE 29
Step 1 Carbonyldiimidazole (24g) was added to a solution of allyl-3,4-dichlorophenyl acetic acid (30.6g) in anhydrous THF (600 ml). The reaction mixture is stirred at 23 ° C for 1 hour. In a separate flask under N2, potassium t-butoxide (16.8 g) is dissolved in anhydrous THF (425 ml). The solution is cooled to 0 ° C and CH3N02 (200 ml) is added for 30 minutes. The acyl imidazole solution is added to the potassium nitranate solution through an addition funnel while maintaining the internal temperature between 0 ° C and 5 ° C. The cooling bath is removed and stirred at 23 ° C for 2 days. The reaction mixture is cooled to 0 ° C and poured into cold 1 M HCl (500 ml). The organic layer is separated, dried (MgSO 4) and concentrated to give 34 g of an orange oil. MS (CI + / CH4) m / e 288 (M + 1).
Step 2: A solution of the product from step 1 (12.2 g) in THF (34 ml) and HOAc (34 ml) is cooled to 0 ° C and H20 (17 ml) is added. Zn powder (15.6 g) is added in portions for 15 minutes. The reaction mixture is stirred for 15 minutes at 0 ° C and then heated to 23 ° C. The reaction mixture is heated at 40 ° C for 3 minutes. Heat is extracted and poured into H20 (150 mL) and THF (100 mL). The mixture is filtered and the solids are washed with THF and H20. The filtrate is concentrated and the resulting orange colored material is washed with Et20 and CH2CI2. The filtrate is concentrated to give 15.5 g of an orange oil. MS (CI + / CH4) m / e 259 (M + 1).
Step 3 A solution of the product from step 2 (15.5 g) in THF (55 ml) and H2O (10 ml) is cooled to 0 ° C and 3,5-dichlorobenzoyl chloride (8.2 g), base, is added. of Hunig (12 ml) and DMAP (0.25 g). The reaction mixture is heated to 23 ° C and stirred for 16 hours. EtOAc (300 mL) is added and washed with H2O (30 mL), 1 M HCl (3 x 30 mL), H2O (2 x 30 mL) and brine (2 x 40 mL), dried (MgSO4), and It is concentrated. Purify (Si02, elute with a gradient of 4% EtOAc / hexanes to give 25% EtOAc / hexanes) in order to obtain 8.8 g of a solid. MS (CI + / CH4) m / e 432 (M + 1)
Step 4 Treat a solution of the product of step 3 (5.7 g, 13 mmol) in EtOH (100 ml) and H20 (25 ml) with CH3ONH2 »HCl (5.54 g, 66.3 mmol) and stir at 23 ° C for 2 days. The mixture is concentrated and EtOAc (200 ml) and H20 (20 ml) are added. Separate the layers and wash the organic layer with 1M NaHCO3 (2 x 20 ml) and brine (20 ml), dry (MgSO4) and concentrate to an oil. Purify (SiO2) eluting with a gradient of 4% EtOAc / hexanes to 15% EtOAc / hexanes to give 1.8 g of clear oil MS (CI + / CH4) m / e 461 (M + 1).
Step 5 Treat the product of step 4 according to a procedure similar to that of example 11, step 5, to obtain the title compound. MS (FAB): m / e 464 (M + 1). The following compounds of formula 29A to 29D were prepared by reaction of the product of step 5 with an appropriate amine (for 29A to 29C see preparation 5A-5C; for 29D, see preparation 306) according to a procedure similar to example 9, stage 9.
EXAMPLE 30
Treat the crude product of example 7, step 1, (1.65 g) with CH3NH2 according to a similar procedure to example 7, step 2, to obtain the desired product (0.6 g). MS (FAB): m / e 464. The product from step 1 is treated with the appropriate carboxylic acid according to a procedure similar to example 8 to give the following compounds:
EXAMPLE 31
Step 1: Treat the product of preparation 7 according to a procedure similar to that described in example 6, step 8. Continue in a manner similar to that described in example 9, steps 8-9, using 4-phenyl-4 -hydroxypiperidine instead of 4-phenylamino-piperidine.
Step 2 Treat the product of step 1 using a procedure similar to example 5, step 4.
Step 3 Treat the product of step 2 in a procedure similar to that of preparation 2, step 4.
Step 4 Treat the product of step 3 (8.4 g) with 2-chloro-6-methylpyridine-4-carboxylic acid (3.84 g), according to a procedure similar to example 8 to give the product (5.9 g).
Step 5 Treat the product of step 4 (3.65 g) with BrCH2CN (0.725 g) according to a procedure similar to example 2A to give the product (1.9 g).
Step 6: Treat the product of step 5, (1.8 g) using a procedure similar to that of Example 4, to give the title compound (1.31 g.) MS (FAB): m / e 675 (M + 1).
EXAMPLE 32
The product of Example 31, Step 4, is rented and deprotected, using a procedure similar to Example 2B, to give the product. MS (FAB): m / e 647 (M + 1).
EXAMPLE 33
The title compound is prepared in a manner similar to the procedures of Example 32 substituting 2- (dimethylamino) -6-methylpyridine-4-carboxylic acid for 2-chloro-6-methylpyridine-4-carboxylic acid and 4-hydroxy-4 -phenyl piperidine by the product of the preparation 3O6. MS (FAB): m / e 661 (M + 1).
EXAMPLE 34
Treat the crude product of example 7, step 1, according to a similar procedure to example 30, substituting MeNH2 in step 1 for NH4OAc and using 3,5-bis (trifluoromethyl) benzoic acid in step 2 to obtain the composed of the title. MS (FAB): m / e 690.
EXAMPLE 35
A procedure similar to that described in Example 18B is used using the product of preparation 5B in place of the product of preparation 306 to obtain the title compound. HRMS (FAB): m / e 672 (M + 1).
EXAMPLE 36
Step 1 4-Piperidone hydrochloride (50 g) was treated in a solution of saturated NaHCO 3 (11) with a dioxane (30 ml) in a solution of benzyloxycarbonyl chloride (53.4 ml). The solution was stirred for 18 hours at room temperature and then extracted with EtOAc (2 x 500 ml). The organic fractions were combined, washed with 1 N HCl (500 ml) and with brine (500 ml), dried over MgSO 4, filtered and evaporated to give 1-benzyloxycarbonyl-4-piperidone (75 g).
Step 2: 2-Bromothioanisole (13.7 g) was cooled in TMF (120 ml) at -78 ° C (internal temperature) and treated with n-BuLi (36.5 ml, 2.5 M hexane solution). After 10-15 minutes, a solution of THF (120 ml) of the product from step 1 (12.5 g) was added through a cannula at -78 ° C. The combined mixture was stirred for a further 18 hours, during which time it was heated to room temperature. The solution was treated with a saturated NH 4 Cl solution (250 ml), EtOAc (250 ml) and the organic layer was separated. The aqueous portion was extracted with additional EtOAc (2 x 250 ml). The organic extracts were combined, washed with H2O (250 ml) and with brine (250 ml), dried over MgSO4, filtered and evaporated to give an oil. Chromatography with silica gel, eluting with EtOAc / hexane mixture, gave 1-benzyloxycarbonyl-4-hydroxy-4- (2-methylthiophenyl) piperidine (9.61 g).
Step 3 The product of step 2 (5.1 g) in CH2Cl2 (50 ml) was treated sequentially with trifluoroacetic acid (8.9 ml) and triethylsilane (34.5 ml). After 18 hours, the solution was treated with saturated NaHCO 3 (150 mk). After one more hour, the organic layer was separated and the aqueous layer was extracted with CH2Cl2 (100 ml). The organic extracts were combined, dried over Na 2 SO 4, filtered and evaporated. The crude product was purified by chromatography with silica gel eluting with EtOAc / hexane mixtures to obtain 1-benzyloxycarbonyl-4 (2-methylthiophenyl) piperidine (3.3 g).
Step 4 The product of step 3 (2.55 g) in CH2Cl2 (30 ml) was cooled to 0 ° C and treated with mCPBA (60%, 2.16 g) and stirred for 1 hour. The reaction mixture was treated with ice (20 g), with a saturated NH 4 OH solution (20 ml) and stirred for 10 minutes. The organic layer was separated and the aqueous layer was re-extracted with CH2Cl2 (2x30 ml). The combined organic portions were dried over MgSO4, filtered and evaporated to give a gum. Chromatography with silica gel eluting with EtOAc / CH 2 C 2 mixtures gave 1-benzyloxycarbonyl-4- (2-methylisulfinylphenyl) piperidine (0.5 g).
Step 5: The product of step 4 (0.5 g) was treated with trifluoroacetic acid (10 ml) and heated at reflux temperature for 45 minutes. The reaction mixture was cooled, diluted with toluene (40 ml) and evaporated. This procedure was repeated twice more. The residue was treated with CH2Cl2 (70 ml) and adjusted to alkaline pH through the addition of a solution of NH4OH. The organic layer was separated, dried over MgSO 4, and filtered and evaporated to give 4- (2-methylsulfinylphenyl) piperidine (0.3 g).
Step 6 Using a procedure similar to Example 9, step 9, the product of step 5 was coupled to the appropriate O-methyloxime to obtain the title compound. Mass spectrum (FAB) 684 (100%). Using the procedures of steps A through E of Example 36, starting with 3-bromothioanisole and 4-bromothioanisole, the corresponding 4- (3-methylsilfinylphenyl) piperidine and 4- (4-methylsulfonylphenyl) piperidine were obtained.
EXAMPLE 37
Step 1 Treat the product of preparation 7 as described in example 20A, adding the amine and using 3,4,5-trimethoxybenzoyl chloride.
Step 2 The product of step 1 was treated using a procedure similar to example 5, step 4.
Step 3: The product of step 2 is alkylated with BrCH2CN according to a similar procedure to example 2A.
Step 4: Treat a solution of the product from step 3 (2.5 g) in CH3OH (37 ml) with NaOCH3 (200 mg). Stir for 18 hours. The resulting solution is treated with CH3ONH2 * HCl and stirred for 3 hours. The solvent is removed and re-suspended in CH 2 Cl 2, dried over MgSO 4, filtered, concentrated in vacuo and purified by chromatography with silica gel (5x20 cm, 5% CH 3 OH / CH 2 Cl 2) to give 2.2 g of the desired product in the form of a white foam. HRMS (FAB) 730.2774 (M + H +). The following formulations exemplify some of the dosage forms of this invention. In each, the term "active compound" refers to a compound of formula I.
EXAMPLE A Tablets
No. Inqredient ma / tablet mq / tablet 1 Active Compound 100 500 2 Lactose USP 122 113 Corn starch, food grade, 3 30 40 as 10% paste in purified water 4 Corn starch, food grade 45 40 5 Magnesium stearate 3 7 Total 300 700
Manufacturing method Items Nos. 1 and 2 are mixed in an appropriate mixer for 10-15 minutes. The mixture is granulated with item No. 3. The wet granules are crushed through a coarse sieve (e.g., inch inch, 0.63 cm) if necessary. The wet granules are dried. Dry granules are sieved if necessary and mixed with item No. 4 and mixed for 10-15 minutes. Item No. 5 is added and mixed for 1-3 minutes. The mixture is compressed to the appropriate size and weighed in a machine suitable for tablets.
EXAMPLE B Capsules
No. Ingredient mg / tablet mg / tablet 1 Active Compound 100 500 2 Lactose USP 106 123 3 Corn starch, food grade 40 70 4 Magnesium stearate at Z Total 250 700
Manufacturing method Items Nos. 1, 2 and 3 are mixed in an appropriate mixer for 10-15 minutes. Item No.4 is added and mixed for 1-3 minutes. The mixture is filled into appropriate two-piece hard gelatin capsules in a suitable encapsulating machine.
EXAMPLE C Sterile powder for injection
Ingredient mq / bottle mq / bottle Sterile active powder 100 500
For the reconstitution add sterile water for injection bacteriostatic water for injection. The in vitro and in vivo activity of the compounds of the formula I can be determined by various methods known in the art, such as an assay for determining the ability to inhibit the activity of the NKi agonist substance P, an NK2 assay of hamster trachea. isolated, an NKi antagonist effects test on a microvascular airway leak induced by substance P, measurement of NK2 activity in vivo in guinea pigs, measurement of bronchoconstriction due to NKA, and receptor adhesion assays Neurokinin Typical procedures have been described in W096 / 34857, published on November 7, 1996. Activity NK3 is determined following a procedure similar to that described in the literature, for example, Molecular Pharmacol., 48 (1995), p.711- 716 The percentage of inhibition is the difference between the percentage of maximum specific adhesion (MSB) and 100%. The percentage of MBS is defined by the following equation, where "dpm" is the disintegration per minute:% MBS = (dpm of unknown) - (non-specific adhesion dpm) X100 (total adhesion dpm) - (dpm of non-specific adhesion)
It will be recognized that the compounds of the formula I exhibit NKi, NK2, and / or NK3 antagonist activity in various degrees, for example, some compounds have a strong NK-? Antagonist activity. but a weaker NK2 and NK3 antagonist activity, while others are strong NK2 antagonists but are weaker NKi and NK3 antagonists. Although compounds having approximate equipotence are preferred, it is also within the scope of this invention to use compounds of unequal NK? / NK / NK3 antagonist activity when clinically appropriate. Preferred compounds of the genus of this invention have a Ki < 10nM for the NK receiver. Also preferred are compounds of formula I having a K < 10 nM for the NK2 receiver. Compounds having a Ki < 10nM for each of the NK1 and NK2 receivers. More preferred are compounds having a Ki < 2 nM for the NK-i receiver and a Ki < 2 nM for the NK2 receiver. The compounds of the invention tested for NK3 have Ki in the range of 0.05 to 50 nM. The compound of Example 11, the only amide specifically described in U.S. Patent 5,696,267, has a Ki of 3.6 for the NK1 receptor and a Ki of 9.2 for the NK2 receptor. Using the test procedures described above, it was found that the exemplified compounds had Ki values in the range of 0.2 to 6 nM, preferably 0.2 to 1 nM, for the NKi receptor, and Ki values in the range of 0.2 to 2.7 nM , preferably 0.2 to 1 nM, for the NK2 receptor.
Claims (7)
- NOVELTY OF THE INVENTION CLAIMS 1. - A compound selected from the group consisting of and diastereomers, enantiomers, rotational isomers, E and Z isomers of the oxime, and pharmaceutically acceptable salts thereof. 2. - A compound of claim 1 selected from the group consisting of
- AH, OH N
- H3C, CH3 C! 3. - A compound of claim 2 selected from the group consisting of
- 4. - A compound of claim 1 which is or a diastereomer, enantiomer, rotational isomer, E and Z isomer of the oxime, and pharmaceutically acceptable salt thereof. 5. - A compound represented by the formula. or a diastereomer, enantiomer, rotational isomer or E and Z isomer of the oxime, or a pharmaceutically acceptable salt thereof, wherein T is R2-phenyl or R3 -pyridyl; R1 is H, methyl, ethyl, -CH2CN, -CH2C (O) NH2, (CH2) 3SO3H, CH2C (O) NHCH3, -CH2C (O) NHOH, -CH2C (O) NHOCH3, CH2C (O) NHCH2CN, CH2F , -CH2C (O) NHCH2SO3H,
- R represents 2-3 substituents independently selected from the group consisting of chlorine, methyl and methoxy; R3 is 2 to 4 substituents independently selected from the group consisting of chloro and methyl; R 4 is methyl, ethyl; and Z is
- 6. - A compound of claim 5 wherein T is R-substituted phenyl, where R 2 consists of two chloro substituents, two methyl substituents, or two methoxy substituents and one methyl substituent, R 1 is methyl, -CH 2 F, -CH 2 CN, -CH2C (O) HCH2SO3H, R is methyl; Zes
- 7. - A compound of claim 6 wherein R consists of two chlorine substituents, R1 is methyl and Z is
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/975935 | 1997-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA00004956A true MXPA00004956A (en) | 2001-07-03 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2218913C (en) | Substituted oximes, hydrazones and olefins as neurokinin antagonists | |
CA2268847C (en) | Substituted oximes derivatives useful as neurokinin antagonists | |
US5250542A (en) | Peripherally selective piperidine carboxylate opioid antagonists | |
JP3242980B2 (en) | Polycyclic amine compound, enantiomer thereof, production method thereof, and pharmaceutical composition containing these | |
US6002009A (en) | Di-substituted 1,4-piperidine esters and amides having 5-HT4 antagonistic activity | |
KR100229117B1 (en) | Piperidine derivatives | |
HUT72065A (en) | Selective antagonistic compounds of human nk3 receptor and their use in pharmaceutical and diagnostical compositions | |
SI9300513A (en) | Basic quaternary amids, procedure for their preparation and pharmaceutical compositions comprising them | |
US5712288A (en) | Quaternary basic amides, method of preparing them and pharmaceutical compositions in which they are present | |
EP1032561B1 (en) | Substituted oximes as neurokinin antagonists | |
HUT73226A (en) | With arylaliphatic and alkyl-groups n-substituted novel amides, method for their preparation and pharmaceutical compositions containing same | |
US6063926A (en) | Substituted oximes as neurokinin antagonists | |
MXPA00004956A (en) | Substituted oximes as neurokinin antagonists | |
US5679693A (en) | 1-azoniabicyclo 2.2.1!heptanes, method of preparing them and pharmaceutical compositions in which they are present | |
US6465489B1 (en) | Ureidopiperidine derivatives as selective human NK3 receptor antagonists | |
AU2007342604A1 (en) | Silylated piperidine derivatives | |
CZ20001388A3 (en) | Substituted oximes as antagonists of neurokinins | |
AU734309B2 (en) | Substituted oximes derivatives useful as neurokinin antagonists | |
AU760434B2 (en) | Amide compounds | |
MXPA01003628A (en) | Ureidopiperidine derivatives as selective human nk3 | |
MXPA97006826A (en) | Esteres y amidas of 1,4-piperidina di-sustitu | |
MXPA99003894A (en) | Substituted arylalkylamines as neurokinin antagonists | |
MXPA99004128A (en) | Substituted oximes derivatives useful as neurokinin antagonists |